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Benzodiazepines are prescribed to relieve anxiety and aid sleep; opioid 
analgesics are prescribed to relieve severe or chronic pain. Both medications 
act as central nervous system depressants and can impair ones ability to drive 
safely. Currently, most epidemiological research has focused on the 
association between these medications and traffic crashes. Yet, the role of 
opioid analgesics and benzodiazepines on crash responsibility is still not 
properly understood. Therefore, we examined the impact of short, 
intermediate, and long half-life benzodiazepines and opioid analgesics on 
crash responsibility by drug half-life and driver age, using a case-control 
design with drivers aged 20 and over involved in fatal crashes in the U.S.A. 
from 1993-2006. Drivers (all with BAC=0) were classified as having no 
benzodiazepines detected versus short, intermediate, or long half-life 
benzodiazepines or no opioid analgesics detected versus present. Cases were 
drivers with at least one potentially unsafe driving action (UDA) in relation to 
the crash (e.g., speeding), a proxy measure for crash responsibility; controls 
had no UDAs recorded. Odds ratios (ORs) of any UDA by benzodiazepines 
half-life and opioid analgesic exposure were calculated, with adjustment for 
age, sex, other medication usage, and prior driving record. Compared with 
drivers not using benzodiazepines, drivers taking intermediate or long half-life 
benzodiazepines demonstrated increased odds of an UDA from ages 25 
(Intermediate OR: 1.59; 95% 01=1.08, 2.33; Long OR: 1.68; 95% 01=1.34, 
2.12) to 55 (Intermediate OR: 1.50; 95% 01=1.09, 2.06; Long OR: 1.33; 95%
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Cl=1.12, 1.57). Drivers taking short half-life benzodiazepines did not 
demonstrate increased odds of an UDA compared to drivers not using 
benzodiazepines. Compared with drivers not using opioid analgesics, odds of 
an UDA were increased from 25 (OR: 1.35; 95%: 1.05, 1.74) to 55 years of 
age (OR: 1.30; 95% Cl: 1.07; 1.58) for a male driver, and from 25 (OR: 1.66; 
95% Cl: 1.32; 2.09) to 65 years of age (OR: 1.39; 95% Cl: 1.17;1.67) for a 
female driver. Given the potential impact of these medications on driver safety, 
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Introduction
In 2006, there were over 40,000 fatal traffic collisions in Canada and the 
United States combined (Statistics Canada, 2008; National Highway Traffic 
Safety Administration, 2007b). This translates into approximately 13 fatalities 
per 100,000 licensed drivers in Canada and 21 fatalities per 100,000 licensed 
drivers in the United States (Statistics Canada, 2008; National Highway Traffic 
Safety Administration, 2007b). Factors that contribute to traffic crashes include 
environmental conditions (such as poorly designed roads, weather, or time of 
day) and vehicles involved (poor design, mechanical failure). However, 
research has shown that driver related factors have the greatest contribution to 
traffic crashes (Hendricks, Fell, & Freedman, 1999). Lack of experience, 
speeding, distracted driving can all result in poor driving that leads to a crash. 
Additionally, impairment related to drugs and alcohol can also contribute.
The impairing effects of alcohol are well established (Jones & Lacey,
2001). Other recreational medications, cannabis for example, have been 
shown to be associated with increased crash risk due to possible driver 
impairment (Bédard, Dubois, & Weaver, 2007). Drugs used for medicinal 
purposes to aid sleep, and relieve anxiety or pain, also have the potential to 
impair drivers and lead to fatal collisions since they are designed to depress 
brain function within the central nervous system (CNS). According to the 
National Highway Traffic Safety Administration in the United States, 
medications that depress the CNS including Narcotics (such as opioid 
analgesics) and benzodiazepines are found in approximately 15% of drivers
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stopped for driving under the influence (DUI), the highest percentages for non- 
recreational drugs (Jones, Shinar, & Walsh, 2003). Currently, most 
epidemiological research has focused on the association of CNS depressants 
and traffic crashes, but their role as a causal factor is still not properly 
understood (Jones et al., 2003). Therefore, we chose to examine the role of 
two of the most prevalent CNS depressants (benzodiazepines and opioid 
analgesics) as a causal factor in fatal traffic crashes.
Benzodiazepine Overview 
Benzodiazepine Uses and Prevalence
It is estimated that approximately 18% of Americans suffer from anxiety 
related disorders in a given year and 10-15% of Americans suffer from a sleep 
related disorder (Zammit, 2007; Kessler, Chiu, Demler, Merikangas, & Walters,
2005). Benzodiazepines, commonly known as tranquilizers and sleeping pills, 
are generally prescribed to treat anxiety or as sleep-aids, but can also be used 
as an anesthetic for outpatient surgery, to relax muscles, to relieve seizures, or 
to help with alcohol withdrawal. They can also be used recreationally, though 
use without a prescription is illegal in many parts of the world including Canada 
and the U.S.A. (Centre for Addictions and Mental Health, 2006). One year 
benzodiazepine use prevalence rates have been reported to range from 6.2% 
to 17.6% (Zandstra et al., 2002). While the prevalence of benzodiazepine use 
has declined over the past 10 years, benzodiazepines are the most frequently 
prescribed sedative-hypnotic for those 65 and over (Bogunovic & Greenfield,
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2004; Centre for Addictions and Mental Health, 2006; Mamdani, Rapoport, 
Shulman, Herrmann, & Rochon, 2005). Further, a recent Canadian study 
demonstrated that as people age, benzodiazepine use for medicinal purposes 
increases (Beck et al., 2005).
Half-Life o f Benzodiazepines
Benzodiazepines can be classified by half-life - the speed of elimination 
expressed in hours that it takes for half of the amount of benzodiazepine 
consumed to leave the body (Ashton, 2006). From a pharmacokinetic 
perspective, a benzodiazepine’s half-life is important as it indicates the speed 
by which the medication affects the CNS and also the potential for cumulative 
effects with repeated doses (Birkett, 1996). It is common for benzodiazepine 
half-life to be dichotomized into two categories, short (half-life elimination < 24 
hours) and long (half-life elimination > 24 hours). Given the quick effect of 
short half-life benzodiazepines on the CNS they are typically used as 
Hypnotics (sleep-aids) while long half-life elimination medications, which work 
in a slower fashion, are used as a sedatives (anti-anxiety, known as 
Anxiolytics), but this is not always the case (Ashton, 1994). For example. 
Alprazolam has a half-life of 6-12 hours but is typically prescribed as an 
Anxiolytic. Benzodiazepines with the shortest half-lives can also be used as an 
anesthetic during outpatient surgery (e.g., midazolam). However, it is also 
important to understand that some benzodiazepines also produce active 
metabolites that can prolong the effect of the benzodiazepine. For example, 
the metabolic process for diazepam -  which has a half-life of between 20-100
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hours, produces the active metabolite desmethyldiazepam which has a half-life 
of 36-200 hours, thus increasing (by almost 100% in diazepam’s case) the 
potential duration of the effect of the benzodiazepine (Ashton, 2006).
Im pact o f Benzodiazepines on the Central Nervous System
In pharmacological terms, benzodiazepines enhance inhibitory 
neurotransmitters that slow down CNS electrical signals (Ree & Cannard,
2006). It is this slowing down of the CNS electrical signals in the brain that can 
help to produce a calming effect. However, adverse effects can also occur and 
these include: over-sedation, drug interactions, memory impairment, 
paradoxical stimulant effects (i.e., the opposite effect of what is expected, 
hyperactivity for example), and depression. Both the intended and adverse 
effects can influence the CNS brain activity producing drowsiness, poor 
concentration, lack of coordination, and mental confusion, all of which can 
impair a person’s ability to drive safely.
Prevalence o f Benzodiazepines in Fatal Crashes
Despite the fact that benzodiazepines are labeled with warnings 
regarding their impact on a person’s ability to drive safely, observational 
studies in Canada, Australia, and Europe, indicate that the prevalence of 
benzodiazepine use is approximately three to six percent among drivers 
involved in fatal crashes (Cimbura, Lucas, Bennett, Warren, & Simpson, 1982; 
Mercer & Jeffery, 1995; Drummer et al., 2003; Carmen, Gomez, Sancho, & 
Alvarez, 2002; Sjogren, Bjornstig, Eriksson, Ohman, & Solarz, 1997). 
Investigators have also studied the prevalence of benzodiazepine use in non-
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fatal crashes in Australia, Asia, and Europe and found it to range between 
three and nine percent (Longo, Hunter, Lokan, White, & White, 2000; Lin, Lee, 
Pan, & Hu, 2003; Mura et al., 2003; Sjogren et al., 1997).
Experimental Studies -  Benzodiazepines
Notwithstanding these data, an important research objective is to 
establish a causal link between the use of drugs and crashes. Some 
researchers have examined the impact of benzodiazepines on various driving- 
related tasks utilizing psychometric tests, driving simulators, and on-road 
driving courses (both open and closed circuit) (Drummer, 2002; van Laar, 
Volkerts, & van Willigenburg, 1992; Harrison, Subhan, & Hindmarch, 1985; 
Brookhuis, Volkerts, & O'Hanlon, 1990; Chung et al., 2005; Kozena, Frantik, & 
Horvath, 1995). Various experimental studies have shown that the 
benzodiazepine diazepam (also know by its brand name Valium) impairs 
coordination, and increases a driver’s braking reaction time and their standard 
deviation of lateral placement (i.e., weaving) (Drummer, 2002). Studies have 
also examined the differences by benzodiazepine half-lives (i.e., short versus 
long). While shorter half-life benzodiazepines (such as oxazepam) affect 
driving skills shortly after consumption, they tend to have little to no impact the 
next morning which is particularly relevant given that they usually are 
prescribed as sleep-aids (Drummer, 2002). Conversely, longer half-life 
benzodiazepines have been shown to adversely affect driving in both morning 
after studies and in studies examining multiple doses spread over several days 
(Harrison et al., 1985; van Laar et al., 1992; Brookhuis et al., 1990; Drummer,
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2002). For example, long half-life benzodiazepines such as flurazepam and 
diazepam have been associated with increased weaving and impaired speed 
control within one to three weeks following treatment initiation (van Laar et al., 
1992; Brookhuis et al., 1990).
Observational Studies -  Benzodiazepines
Analyses based on health record datasets provide further evidence that 
benzodiazepine use may be related to crashes. For example, drivers 
demonstrated increased odds of a crash during the time period of a current 
benzodiazepine prescription compared to an earlier time period when they did 
not have a current benzodiazepine prescription (Barbone et al., 1998).
Barbone’s study sample included approximately 20,000 drivers involved in a 
crash and the outcome was a first crash within the study period. Approximately 
96% of the sample had a confirmed blood alcohol concentration (BAG) of zero. 
The odds of crash involvement were 100% higher for users of Anxiolytic type 
benzodiazepines (OR; 2.03; 95%CI: 1.4; 2.9) compared to when the drivers 
were not prescribed this medication. Interestingly, Barbone also examined 
benzodiazepines by half-life (short: < 6 hours, intermediate: 6-24 hours, and 
long: > 24 hours) and found that intermediate and long half-life 
benzodiazepines significantly increased the odds of a crash but short 
benzodiazepines did not. The contribution of benzodiazepines to 
hospitalizations due to a traffic injuries has also been examined (Neutel, 1995). 
Neutel found significant increases in hospitalizations due to a traffic injury for 
those drivers prescribed either Anxiolytics (OR:5.6; 95%CI: 1.7, 18.4) or
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Hypnotic benzodiazepines (OR: 6.5; 95%CI: 1.9, 22.4), particularly for those 
benzodiazepines recently prescribed. It has also been demonstrated that as 
the frequency of benzodiazepine prescriptions increased (one script versus 
three or more, over a six month period), the risk of accident related (traffic or 
otherwise) medical encounters increased (Oster, Huse, Adams, Imbimbo, & 
Russell, 1990). In Tennessee Medicaid recipient drivers 65 years of age and 
older, Ray found a dose-response relationship. Increased doses of 
benzodiazepines (primarily long half-life benzodiazepines) were associated 
with increased odds of a crash with injury (Ray, Fought, & Decker, 1992).
Further, older drivers whose exposure to long half-life benzodiazepines was 
recent had increased odds of a crash involving at least one hospitalization 
(OR: 1.45; 95%CI: 1.04, 2.03) (Hemmelgarn, Suissa, Huang, Boivin, & Pinard,
1997). However, those exposed to short half-life benzodiazepines did not 
demonstrate increased odds, regardless of exposure duration, a result which 
parallels those found in experimental research.
The main strength of these observational studies is the large samples 
they relied on. However, an important limitation is that they examined crash 
involvement rather than driver responsibility for crash initiation. For example, 
the outcome for Hemmelgarn’s study was involvement in a crash resulting in 
injury (Hemmelgarn et al., 1997). A second limitation is the reliance on a proxy 
marker of exposure, such as a current prescription for benzodiazepine (Ray et 
al., 1992). Proxy exposure measures can lead to over-representation in the 
exposed group and under-representation in the non-exposed group (i.e., the
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prescription was filled but not used). The third limitation is the population 
source of the health record. Data sources drawn from a specific sub­
population, for example public health insurance (e.g., Medicaid recipient 
eligibility is determined by economic status), can limit the generalisability of 
results. A fourth limitation is in the classification of benzodiazepines. Most 
studies either group the benzodiazepines as a whole or divide exposure by 
benzodiazepine type (Anxiolytic, Hypnotic). For example, in both Oster and 
Ray’s studies, benzodiazepines were grouped as a whole regardless of half- 
life (Oster et al., 1990; Ray et al., 1992). Alternatively, Neutel classed 
benzodiazepines as either Anxiolytic or Hypnotic -  unfortunately the half-lives 
of their groupings overlapped considerably (2-250; 4-200 hours) (Neutel,
1995). A fifth limitation is the number of cases who used benzodiazepines in 
the data sources. While the samples may be large, the actual number of cases 
exposed to benzodiazepines may be too small to have sufficient statistical 
power. For example. Drummer examined Australian forensic reports of fatally 
injured drivers to determine if crash culpability increased under the influence of 
alcohol and drugs. While crash culpability was 27% higher when 
benzodiazepines were detected in the blcsu (no other drugs or alcohol) this 
increase did not achieve statistical significance - most likely due to the small 
number of benzodiazepine only impaired drivers. (OR:1.27; 95%CI: 0.5, 3.3) 
(Drummer et al., 2004). While Drummer’s sample included almost 2000 
drivers, only 34 tested positive for benzodiazepines alone.
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Opioid Analgesics Overview 
Pain Prevalence
According to the National Center for Health Statistics, an estimated 76.5 
million (26%) Americans, aged 20 and over, reported suffering from pain 
lasting greater than 24 hours (National Center for Health Statistics, 2006). Of 
these, 56% reported suffering from pain lasting greater than 3 months 
(National Center for Health Statistics, 2006). Prevalence rates of chronic pain 
vary widely; partly due to different definitions of pain duration and also due to 
survey method employed (for example, self-report survey versus clinical 
examination) (Verhaak, Kerssens, Dekker, Sorbi, & Sensing, 1998).
Regardless, prevalence rates vary from as low as two percent to as high as 
40% (Verhaak et al., 1998; Mantyselka, Turunen, Ahonen, & Kumpusalo,
2003). Several conditions can be the source of pain and some include: cancer, 
osteoarthritis, fibromyalgia, and lower back pain. Often, prescription analgesics 
are used to help manage mild to severe acute and chronic pain associated 
with these conditions.
Prevalence o f Prescription Analgesics
There are two classes of prescription analgesics: opiate and non­
steroidal anti-inflammatory drug (NSAID) based. Prescription analgesic 
prevalence rates have been studied using both population-based surveys 
(Antonov & Isacson, 1998; Paulose-Ram et al., 2003; Turunen, Mantyselka, 
Kumpusalo, & Ahonen, 2005; Sawyer, Bodner, Ritchie, & Allman, 2006) and 
through examination of prescribing patterns found in pharmaceutical
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databases (Eggen & Andrew, 1994; Blackburn, Downey, & Quinn, 1990). 
Regardless of method of study, prevalence rates for prescription analgesics 
tend to be between 8 -  10% (Turunen et al., 2005; Blackburn et al., 1990;
Eggen et al., 1994; Sawyer et al., 2006; Antonov et al., 1998). Some studies 
break down prevalence rates by analgesic type (NSAID, opiate) (Eggen et al., 
1994; Paulose-Ram et al., 2003; Sawyer et al., 2006). For example, Paulose- 
Ram examined self-reported prescription analgesic use that was captured in a 
representative sample of United States civilians (n=20,050) using the National 
Health and Nutrition Examination Survey (Paulose-Ram et al., 2003). While 
overall monthly prevalence of prescription analgesics was over 9%, the 
monthly prevalence rate for those on opiate based analgesics was 3.4% 
(Paulose-Ram et al., 2003).
Prevalence studies have demonstrated analgesic use increases with 
age. In 1994, Eggen and Andrew reported on analgesic prescriptions 
dispensed in a sample of the Norwegian population (Eggen et al., 1994). The 
overall user proportion of controlled analgesics during the one year period 
studied increased from 7.8% (aged 20-39) to: 12% for those aged 40-59, 15% 
for those aged 60-79, and 19.4% for those aged 80+ (Eggen et al., 1994). 
Comparable results by age were reported in Blackburn’s study of a Canadian 
provincial pharmaceutical database where prevalence of use of mood 
modifying drugs (including analgesics) Increased by age (Blackburn et al.,
1990).
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There is also evidence which suggests prescription analgesic use may 
differ by sex. For example, Antonov and Isacson found 12.2% of women 
reported prescription analgesic use compared with only 7.2% of men (Antonov 
et al., 1998). Eggen and Andrew reported female use of prescription 
analgesics was greater than males (8.9% vs. 6.8% p<.0001) (Eggen et al.,
1994). Most analgesic users studied by Eggen and Andrew reported they 
consumed a little less than a month’s worth of medication a year, however, 
approximately 15% of users reported consuming the medications on a weekly 
or even daily basis throughout the entire year studied. In these weekly to daily 
users, the proportion increased from 3.2% (aged 0-19) to 34.6% (aged 80+) in 
women, and 0.0% (age 0-19) to 26.8% (aged 80+) in men -  both age and sex 
were statistically significant (p<.0001 for both age and sex) (Eggen et al.,
1994).
The influences of other factors, such as the user’s health and economic 
status, have also been examined in relation to prevalence rates. Turunen and 
colleagues performed a cross-sectional study of analgesic use in 
approximately 3300 Finns. Along with age and sex, Turunen also included 
indicators of: health (mood status and chronic disease presence), 
socioeconomic status (education and work status), and pain (frequency, 
duration, and intensity) (Turunen et al., 2005). A lack of formal education, 
unemployment, the presence of a chronic disease, a low mood score 
(indicating possible depression), and chronic, average to severe intensity, pain 
all significantly increased the odds of analgesic use. Even with these
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additional factors accounted for, those participants aged 45 and older had 
twice the odds of consuming analgesics on a daily basis compared to those 
who did not (Turunen et al., 2005). On the other hand, older age did not 
significantly increase the odds of a person using opioid analgesics on an as 
needed basis. Also the odds of consuming analgesics did not significantly 
differ by sex when all variables were accounted for.
Antonov and Isacson examined analgesic use as reported in a 
structured interview of a probability sample (N=11,996) of all inhabitants of 
Sweden aged 1 8 - 8 4  years of age (Antonov et al., 1998). Poor health status 
(smoker, over-weight, poor self-perceived health, and poor physical function), 
pain severity, and a recent visit to a health care provider (physician or physical 
therapist) significantly increased the odds of prescription analgesic use in both 
men and women (Antonov et al., 1998). However, age did not significantly 
increase the odds of prescription analgesic use when health status, pain 
severity, and a visit with a health care provider were accounted for.
While both Turunen (Turunen et al., 2005) and Antonov (Antonov et al.,
1998) look at several possible reasons for increased opioid use, neither 
authors' study discriminated between NSAID and opiate based prescription 
analgesics when querying participants. It is quite possible that along with age, 
sex, pain severity, and health status the type of analgesic prescribed can also 
influence prevalence rates. Sawyer et al’s examination of medication use in 
community-dwelling older adults (> 65 years of age) did discriminate between 
NSAID and opiate based prescription analgesics (Sawyer et al., 2006).
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Approximately 31% of participants reported taking prescription analgesics at 
the time of the assessment - 25% reported taking a prescription NSAID and 
8.5% reported using an opiate based analgesic (numbers do not add up due to 
some participants reporting multiple medication usage) (Sawyer et al., 2006).
Finally, opioid analgesic consumption is on the increase. According to 
the International Narcotics Control Board, in the United States of America 
consumption of the major opioid analgesics, including codeine, hydrocodone, 
morphine, oxycodone, and methadone increased by approximately 38% 
between the years 2001 and 2005. (International Narcotics Control Board,
2007)
Prescription Analgesics and Driving: Adverse Effects, Experimental, and  
Epidemiological Evidence.
Opioid analgesics can be used to help manage mild to severe acute 
and chronic pain. Colloquially known as “pain killers", common opioid 
analgesics include: codeine, hydrocodone (vicodin), methadone, and 
morphine. The route of administration varies, though it is typically either 
through oral (tablet, syrup) or parenteral (injection) forms. Along with pain 
management, opioid analgesics can also be used as a cough suppressant, for 
substance abuse withdrawal, and to aid anesthetic in surgery. According to the 
American Pain Foundation, the most common adverse effects of opioid based 
analgesics include nausea, sedation (sleepiness), and mental clouding (Altilio 
et al., 2007). Other adverse effects can include dizziness and memory
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impairment (Altilio et al., 2007). These adverse effects can influence the CNS 
potentially impairing a person’s ability to drive safely.
Current Evidence  -  Experimental
Using cognitive, laboratory, and on-road evaluations, researchers have 
examined the potential impact of opioid analgesics on driving ability (Bruera, 
Macmillan, Hanson, & MacDonald, 1989; Galski, Williams, & Ehle, 2000;
Vainio, Ollila, Matikainen, Rosenberg, & Kalso, 1995; Byas-Smith, Chapman, 
Reed, & Cotsonis, 2005; Gaertner et al., 2006). In general, studies evaluating 
driving ability demonstrate small differences between opioid analgesic users 
and control groups. For example, Vainio and colleagues examined driving 
ability in cancer patients receiving long-term morphine analgesia (Vainio et al.,
1995). Specifically, Vainio compared 24 cancer patients on a stable dose of 
slow-release morphine tablets with 25 cancer patients reporting no pain and 
who did not take regular analgesics. The psychomotor tests administered, 
were designed for professional drivers and measured basic non-verbal 
intelligence, vigilance, task concentration, divided attention, and fluency of 
motor reactions. While no significant differences were found between 
morphine and control groups, the authors reported that the morphine groups’ 
responses were generally (but not statistically significantly) worse than the 
control groups. Given the relatively small sample size of this study, it is 
possible that the statistical comparisons lacked sufficient power to 
demonstrate a statistically significant difference. Regarding the neurological 
tests, the morphine group performed significantly worse on the test of balance
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(i.e., increased body sway in cm) when eyes were closed (p=.028), but 
performed significantly faster on the finger-tapping test (p=.023) -  however, 
while the association between medication and neurological tests was 
significant, one cannot rule out the effect that the pain itself may have had. 
Interestingly, the authors found moderate correlations between plasma 
concentrations of morphine and performance on the Q1 (test of attention 
capacity) and strong correlations between plasma concentrations and LL5 (test 
of concentration and structuring ability) errors performed.
Galski and colleagues performed a pilot study which evaluated the 
effects of Chronic Opioid Analgesic Therapy (COAT; greater than 6 month 
history of responsiveness to opioids for pain reduction and current use of a 
long acting opioid). They compared patients suffering from nonmalignant pain 
(e.g., osteoarthritis, fibromyalgia) (Galski et al., 2000) to historical control of 
327 drivers, who had a history of stroke, traumatic brain injury, or anoxia. The 
historical control was divided into two groups: Driver’s who had passed a 
behind the wheel test following rehabilitation (N=162); and driver’s who had 
failed (N=165). Driving ability was measured with both a comprehensive 
battery of psychometric tests and with a one hour driving simulation that 
captured errors in braking, steering, accelerating, controlling speed, and 
signaling. The COAT patients equaled or exceeded both control groups’ 
scores in all but one measure of driving-related ability. However, while COAT 
patients had faster completion times, they did so at the expense of accuracy.
For example, on the Double Letter Cancellation Test (a test of visual scanning)
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COAT patients committed twice as many errors compared to the control group 
who had passed their behind the wheel test (Galski et al., 2000).
In 2005 Byas-Smith compared driving ability between a convenience 
sample of those suffering from chronic pain under a stable opioid dosing 
regime, those suffering from chronic pain that chose not to use opioids, and a 
group of healthy normals. Driving ability was measured with both cognitive and 
on-road tests. While Byas-Smith found no statistically significant differences 
between the groups using attention-based tests, the normal group scored 
significantly faster compared to both chronic pain groups (opioid and non­
opioid) on the Digit Symbol Substitution Test -  which measures the speed by 
which visual information is processed and then translated into motor activity 
(Byas-Smith et al., 2005). The on-road test included both an obstacle course 
where speed and error rates were captured and a community drive where 
speeding, turning, stopping, and lane infractions were examined. For the 
obstacle course, Byas-Smith found no significant differences between the 
three groups in completion speed or error rate for the on-road obstacle course. 
During the community drive, only speeding infractions were recorded and there 
were no turning, stopping, or lane violations across the three groups. Speed 
exceedances ranged between 5 and 15 mph and there were no statistically 
significant differences between driver groups.
Another approach to assess the possible impairment of opioid 
analgesics was taken by Gaertner and colleagues (Gaertner et al., 2006).
Their study compared driver related cognition and psychomotor performance
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of 30 chronic non-cancer pain patients, currently treated with controlled 
release oxycodone, with 90 healthy volunteers whose scores were adjusted for 
an intoxication effect equivalent to > 0.05 blood alcohol content (Gaertner et 
al., 2006). Volunteers were considered to be a representative sample of 
drivers from the German population. Each patient was assessed for 
performance under pressure, orientation, concentration, attention, and reaction 
time. Patients on oxycodone in general scored statistically significantly higher 
than the control group scores adjusted for the effect of alcohol. Compared with 
the control group, oxycodone patients had: significantly faster mean reaction 
times for the test of attention; scored better on the test of visual orientation, 
tachistoscopic perception with fewer wrong answers; better motor coordination 
represented by less time off track; and, a higher vigilance score with 
significantly fewer wrong answers. However, the authors found that daily 
oxycodone dosage correlated moderately with the number of wrong answers 
on the test of attention. Also, age was found to have a strong, positive, 
correlation with increased mean times and higher (poorer) scores of motor 
coordination and have a moderate correlation with reaction times for the test of 
visual orientation. Conversely, driving experience was shown to have a 
moderate negative correlation with reaction times on the test of visuai 
orientation.
It should be noted that in all of the above listed studies, participants 
using opioid analgesic therapy received a stable treatment dose. One could 
hypothesize those patients on long term therapy (i.e., stable dosing) would be
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at the least risk of driver impairment and consequently be responsible for the 
small effect sizes found in the studies described above. There is evidence to 
suggest that dosage state (increased versus stable) is associated with 
impaired driving ability. Bruera and colleagues examined the impact of 
prescription analgesics on cognition for those patients suffering from cancer 
pain (Bruera et al., 1989). Cognitive measures included finger tapping, 
arithmetic, memory for digits, and visual memory tests. Twenty patients were 
on a stable dosing regime and the other twenty had received an increased 
dosage of > 30% within the past 3 days. Comparing the cognition change 
scores between the two groups demonstrated that the increased dosage 
groups’ differences were significantly greater than the stable groups (Bruera et 
al., 1989) suggesting that increased dosing can result in the patient 
experiencing cognitive impairment.
Current Evidence  -  Observational
Similar to experimental evidence, most observational studies 
demonstrate small or non-significant differences between those drivers taking 
prescription analgesics and a variety of risks including intoxicated driving, 
involvement in a motor vehicle crash, and crash fatalities (Fishbain, Cutler, 
Rosomoff, & Rosomoff, 2002; Blomberg & Preusser, 1974; MacPherson, Perl, 
Starmer, & Homel, 1984; Holmgren, Loch, & Schuberth, 1985; Christensen, 
Nielsen, & Nielsen, 1990; Marquet et al., 1998; Gjerde, Beylich, & Morland,
1993; Honkanen et al., 1980; Skegg, Richards, & Doll, 1979; Ray et al., 1992; 
Leveille et al., 1994). In 2002, Fishbain et al conducted a structured evidence-
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based review of studies from 1966 on containing epidemiological evidence 
regarding associations between opioid use with: (1) intoxicated driving, (2) 
motor vehicle crashes, and (3) motor vehicle fatalities (Fishbain et al., 2002).
The quality of evidence was rated according to the Agency for Health Care 
Policy and Research Rating Scale I where evidence is rated between - (I) 
Meta-analysis of multiple-well designed studies (considered the strongest 
level) and (V) Case reports and clinical examples (considered the weakest 
level) (West et al., 2002). After assessing the evidence, the authors concluded 
that opioids were probably not associated with intoxicated driving, motor 
vehicle crashes, or motor vehicle fatalities (Fishbain et al., 2002).
Of the six studies Fishbain included which examined the association 
between opioid use and intoxicated driving, five compared opioid detection 
rates to general population reported prevalence of opioid use, and one 
reported differences in traffic convictions between methadone users and a 
driver control group. Of the five prevalence studies, opioids detected in drivers 
suspected of intoxicated driving were approximately one tenth of the estimated 
point prevalence for opioid use reported in two studies for the general 
population of the USA and Norway (Simoni-Wastila, 2000; Eggen et al., 1994).
In the study which compared traffic convictions, no significant differences in 
the proportion of traffic convictions was found between drivers recovering from 
heroin addiction on methadone treatment and a matched (same sex, similar 
age) non-user of opioid analgesics control group (Blomberg et al., 1974).
Given the low prevalence rate of opioid detection in drivers suspected of
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driving under the influence, and the similar levels of traffic convictions found, 
Fishbain concludes that opioids are not likely to be associated with intoxicated 
driving.
However, these five studies were assessed as Type IV evidence -  well 
designed non-experimental studies -  and have limitations and inherent biases 
that need to be considered when evaluating the possible association between 
opioids and intoxicated driving (West et al., 2002). For example, sample 
selection for two of the five studies was based on drivers suspected of driving 
under the influence of alcohol by police officers (MacPherson et al., 1984; 
Holmgren et al., 1985). We cannot assume that drivers under the influence of 
opioid analgesics would exhibit the same characteristics as an inebriated 
driver. Another limitation of these studies is that the sample may not be 
representative of opiate users. For example, the sixth study regarding 
intoxicated driving and opiate use, rated by Fishbain as type II evidence (a well 
designed experimental study) consisted primarily of young males (mean age 
27.1 years; 89% male) (Blomberg et al., 1974). Of the opiate analgesic groups’ 
self reported miles driven in this study, approximately one third of miles driven 
per year were contributed by unlicensed drivers (Blomberg et al., 197 II is 
quite plausible that this sample is representative of drivers recovering from 
heroin on methadone treatment, but would most likely not be representative of 
patients using opioid analgesics for other purposes, in particular pain relief.
In regard to the association between opioids and motor vehicle crashes, 
Fishbain reported on 11 studies of Type II (well-designed experimental study)
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and III (well-designed quasi-experimental study) levels of evidence. Fishbain 
reported that ten of the eleven studies indicated opioids were not associated 
with motor vehicle crashes. For example, Christensen examined drug 
influence on Danish drivers (N=461) involved in motor vehicle crashes 
suspected of driving under the influence (Christensen et al., 1990). Opioids 
were detected in 38% of cases (N=173) suspected of driving under the 
influence, the second highest drug group after benzodiazepines (65%).
However, of all drivers testing positive for opiates only 23% (N=40) were 
involved in a traffic crash versus 77% not involved in a crash (p<.0001) 
(Christensen et al., 1990). Marquet compared the presence of opiates in young 
French drivers (aged 18 -  35) injured in a motor vehicle crash with control 
group admitted to the same emergency units as drivers for non-traumatic 
reasons (Marquet et al., 1998). Of the drugs tested among injured drivers, 
opiates (with a 10.5% prevalence rate) were the second highest drug detected 
after cannabinoids. Yet, this prevalence rate was almost identical to the opiate 
prevalence rate for the non-trauma injury control group (10.4%) (Marquet et 
al., 1998). Given the evidence, Fishbain concludes that opioids are likely not 
associated with motor vehicle crashes.
Of the 10 (all type IV evidence) studies examined by Fishbain (Fishbain 
et al., 2002) addressing whether opioids are associated with motor vehicle 
crash fatalities, nine reported an opioid prevalence in fatally injured drivers 
between 0.3% and 3.9% (Fortenberry, Brown, & Shevlin, 1986; Mason &
McBay, 1984; Cimbura et al., 1982; Garriott, DiMaio, Zumwalt, & Petty, 1977;
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Gjerde et al., 1993; Williams, Peat, Crouch, Wells, & Finkle, 1985). The 
remaining two studies reported a 0% prevalence rate (Owens, McBay, & Cook, 
1983; Budd, Muto, & Wong, 1989). For example, Owens and colleagues 
studied the incidence of alcohol and other drugs in North Carolina drivers killed 
in single car crashes for a one-year period (Owens et al., 1983). Of the 169 
drivers meeting study criteria, 53% (n=90) of the fatally injured drivers were 30 
years of age and under, and 83% of drivers were male. Approximately 67% of 
drivers tested positive for alcohol, 5.9% and 5.3% were THC or barbiturate 
positive respectively. None of the drivers tested positive for opiates. Budd and 
colleagues examined serum from autopsies of 102 fatally injured drivers over a 
six month period (Nov ’85 thru April ’86) and in a second study, 492 fatally 
injured drivers over a one-year period (May ’87 thru May ’88) from Los Angeles 
County (Budd et al., 1989). In the first study of 102 fatally injured drivers, 
approximately 64% (n=65) were positive for alcohol and/or drugs. Yet, only 
one case (0.9% of drivers) tested positive for opiates (codeine). In their second 
study of 492 fatally injured drivers, no cases tested positive for opiates.
Similar to Budd and Owens, others have found only small numbers of 
fatally injured drivers testing positive for opiates. Fortenberry and colleagues 
examined 1518 Alabama drivers fatally injured in a traffic crash found almost 
no opioid presence (Fortenberry et al., 1986). Less than 0.3% tested positive 
(N=4) for propoxyphene, an opioid analgesic. In Mason’s study of 600 fatally 
injured North Carolina drivers, opioids were detected in 0.3% (N=3) cases 
(Mason et al., 1984). Given the results of the studies above, and that the other
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studies examined reported an opioid prevalence well below North American 
standards, Fishbain concludes that the current evidence does not support an 
association between opioid use and vehicle crash fatalities (Fishbain et al.,
2002).
While Fishbain’s conclusions are generally supported by the 
epidemiological evidence, there are limitations of the studies that should be 
considered. For example, alcohol and other drug use in conjunction with opioid 
analgesics can also be an issue in interpreting associations between opiate 
use and traffic crashes or fatalities. Marquet found a significantly higher 
prevalence of opiates in male drivers, injured in a traffic crash, who also tested 
positive for cannabinoids compared to those drivers who tested negative for 
cannabinoids (Marquet et al., 1998). Christensen found that 54% (N=250) of 
their sample of drivers suspected of driving under the influence tested positive 
for two or more drug groups (Christensen et al., 1990). In a study of 159 fatally 
injured car drivers in Norway, Gjerde found that 12 (7.5%) were alcohol and 
drug positive (Gjerde et al., 1993). One of the 12 cases (representing 8.3% of 
those alcohol and drug positive) tested positive for therapeutic levels of 
Codeine and a BAC of 0.2 (Gjerde et al., 1993). MacPherson demonstrated 
that the combination of opioid analgesics (e.g.. Codeine) and lower levels of 
alcohol (BAC < 0.115) were associated with increased crash risk (between 45 
to 65%, p <.01 ) in young male Australian drivers compared to those testing 
positive for alcohol only (MacPherson et al., 1984).
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It is also possible that analgesics are under-detected in epidemiological 
studies using serum (blood/urine) analyses. Like Marquet, Honkanen also 
examined the prevalence of drugs in drivers admitted to emergency room 
department (Honkanen et al., 1980). Along with urine and blood analyses, 
Honkanen also obtained self-report drug usage from the drivers. While no 
analgesics were detected in the serum analysis, 21% of drivers involved in 
traffic crashes reported using analgesics within the last week (N=41). Of these 
41 drivers, nine reported using an analgesic within the past 24 hours 
(Honkanen et al., 1980). Walsh examined the prevalence of alcohol and other 
drug use among adults involved in motor vehicle crashes admitted to a trauma 
center (Walsh et al., 2004). This study found that if tested for alcohol use only, 
45.2% would not have been identified for drug use.
Sometimes epidemiological studies can be limited by the size of the 
exposed group. Skegg and colleagues compared pharmacy prescriptions for 
57 drivers involved in a crash (requiring hospital admission or resulting in 
death) with a randomly selected control group (N=1,425) matched on general 
practitioner, sex, and year of birth (Skegg et al., 1979). Of the 57 drivers 
involved in a crash, 7% (N=4) had received a prescription for minor analgesics 
versus 3.1% (N=44) of the 1425 control group members, resulting in a non­
significant Relative Risk of 2.5. Unfortunately, Skegg’s study was severely 
limited by the exposure sample and also the measure of exposure. Of the 57 
drivers involved in crashes, 21 (37%) were driving cars, 22 (39%) motorcycles, 
and 14 (24%) bicycles. Further, the majority of the drivers involved in crashes
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were males (N=44, 77%) with two thirds below 30 years of age (N=36, 63%). 
Skegg and colleagues contended that the power of their study was limited by 
the measure of medication exposure, a prescription filled within the last 3 
months prior to the crash (Skegg et al., 1979).
Many epidemiological studies that indicate little or no association 
between opioids and unsafe driving have samples that are usually: a) 
comprised of younger drivers (Blomberg et al., 1974; Marquet et al., 1998; 
Maddux, Williams, & Ziegler, 1977; Skegg et al., 1979; Williams et al., 1985); 
or b) include a distribution that is positively skewed towards younger drivers 
(Mason et al., 1984; Honkanen et al., 1980; Owens et al., 1983; Cimbura et al., 
1982; Williams et al., 1985); or c) do not indicate age of the drivers sampled 
(Budd et al., 1989). Additionally, in many of these epidemiological studies, 
females are under-represented -  usually consisting of less than 20% of the 
drivers studied (Blomberg et al., 1974; Marquet et al., 1998; Maddux et al.,
1977; Christensen et al., 1990; Skegg et al., 1979; Owens et al., 1983; Mason 
et al., 1984; Williams et al., 1985). It is plausible that the under-representation 
of both older and female drivers means that they are less involved in traffic- 
related incidents associated with opioid use. Yet, given that opioid prevalence 
has been demonstrated to be greater in females than males and has also been 
shown to increase with age (Eggen et al., 1994; Blackburn et al., 1990;
Antonov et al., 1998), it is also plausible that the low reported prevalence of 
opioid analgesics and their minimal association with unsafe driving is driven by 
the characteristics of the sample. For example, less than 2% of fatally injured
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drivers tested positive for opioid analgesics in Williams’ study but the entire 
sample was comprised of male drivers between the ages of 15-34 -  a sample 
we would expect a low prevalence of opioid analgesic use (Williams et al.,
1985).
In studies that have examined older drivers at risk when using opiates, 
the results are inconclusive. Christensen did find drivers involved in a crash 
were significantly older, but as discussed earlier, did not detect a positive 
association between opioid use and traffic crashes (Christensen et al., 1990).
In a sample of Tennessee Medicaid recipient drivers 65 years of age and 
older, Ray found no increased risk of involvement for an injurious crash for 
current users of opioid analgesics (relative risk =1.1; 95% Cl: 0.5; 2.4) (Ray et 
al., 1992). Leveille found a non-significant trend towards elevated risk of injury 
collisions in those drivers 65 and older as the probability increased that they 
were taking the medication on the day the crash occurred (Leveille et al.,
1994). However, Leveille observed significantly higher odds (when adjusted for 
race, marital, education, and diabetic status) of an injurious crash (Adjusted 
CR: 1.8; 95% Cl: 1.0; 3.4) in drivers who had filled their opioid prescription 
within the past 60 days (Leveille et al., 1994). It should be noted that the 
discrepancy between Ray and Leveille’s studies may be due to differences in 
their exposure measure for opioids. Unlike Ray, Leveille included codeine- 
containing cough medications and these accounted for one of every five opioid 
prescriptions (Leveille et al., 1994).
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Finally, studies have shown that the prevalence of opioid analgesic 
drugs detected in drivers is increasing. Drummer examined the prevalence of 
drugs, including opioids, in drivers killed in Australian road traffic crashes over 
a 10 year period (Drummer et al., 2003). The prevalence of opioids doubled 
from 3.4% (n=36) during the period of 1990-1993 to 6.6% (n=93) during the 
period of 1997-1999. Jonasson, through blood testing, also found that the 
prevalence of dextropropoxyphene, an opioid analgesic increased from 2.6% 
in 1992 to 4.3% in 1997 (Jonasson, Jonasson, Saldeen, & Thuen, 2000) in 
drivers suspected of driving under the influence of an intoxicating substance.
Purpose
Based on current evidence we set out to design a study that: a) 
examined the impact of both benzodiazepine and opioid analgesics exposure 
on driver error (versus crash involvement): b) was based on a representative 
data source with high external validity; c) measured drug exposure with 
standardized toxicological testing, and d) contained benzodiazepines 
representing all ranges of half-lives and all major opioid analgesics. Further, 
we wanted a data source with both the capacity and content to control for other 
factors that may contribute to crash initiation, such as age, sex, previous 
driving history, and other substances that may affect the CNS, such as alcohol 
and other medications. Specifically, we examined the contribution of both 
benzodiazepine and opioid analgesic exposure to driver error in fatal crashes 
in all U.S. fatal crashes from 1993 to 2006. Given both the experimental and
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epidemiological evidence reviewed and the known effects of benzodiazepines 
and opioid analgesics on the CNS, we hypothesized that the odds of an unsafe 
driver action would be significantly increased for those drivers who were taking 
intermediate or long half-life benzodiazepines or opioid analgesics.
Methods
Data source
In 1975, the National Center for Statistics and Analysis of the National 
Highway Traffic Safety Administration, U.S.A., developed the Fatality Analysis 
Reporting System (FARS) (National Highway Traffic Safety Administration,
2006). This database contains fatal traffic crash information from the 50 states, 
District of Columbia, and Puerto Rico from 1975 to the present. Crashes 
included in FARS meet two criteria: 1) the crash involves a motor vehicle 
traveling along a traffic way customarily open to the public; and 2) the crash 
results in the death of a person (either an occupant or non-motorist) within 30 
days of the crash.
Data are gathered from the following sources: police reports; vehicle 
registration and driver licensing files; state highway department data; vital 
statistics; death certificates, coroner, medical, emergency service, and hospital 
reports(National Highway Traffic Safety Administration, 2006). All data 
elements obtained from these sources are reported onto one of three forms 
(accident, vehicle, and person) by trained FARS analysts. The accident form 
contains crash information specific to the time, location, road and weather 
conditions, and overall vehicle information. More specific vehicle information.
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such as: vehicle type, crash role, points of impact, the most harmful event, and 
drivers record and license status, is recorded on the vehicle form. Finally, a 
person form contains data for each person involved in the crash. Information 
recorded includes: age, sex, role, alcohol and drug involvement, injury 
severity, et cetera. In terms of drug involvement, the FARS database captures 
approximately 300 separate drugs with impairment potential which fall into one 
of 8 groupings (narcotic, depressant, stimulant, hallucinogen, cannabinold, 
phencyclidine (PCP), anabolic steroid, and inhalant). Given, the quantity of 
information coded in the database, and number of crashes recorded, the 
FARS database allows for the control of numerous potential confounders, and 
calculation of crash estimates more easily generalized to all drivers involved in 
fatal crashes (Dischinger, Ho, & Kufera, 2000).
Data Assem bly
Data Retrieval.
On an annual basis, the National Highway Traffic Safety Administration 
(NHTSA) updates the FARS data available via the FARS File Transfer 
Protocol (FTP) site (National Highway Traffic Safety Administration, 2007a).
While the data is contained on three forms (Accident, Vehicle, Person) the 
data is captured in four datasets: Accident, Vehicle, Person, and Driver. For 
the years 1993 through 2003, data was downloaded from the FARS FTP site 
in structured query language (SQL) format. For data in SQL format, one yearly 
data file is provided containing all four levels of crash data (Accident, Vehicle, 
Driver, and Person). To allow analysis of this data, each crash data level was
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extracted into its own data file (Accident, Vehicle, Person) by year. Between 
2004 and 2006, the SQL format was no longer available; therefore data was 
downloaded in the available Statistical Analysis Software (SAS) format. For 
data in SAS format, each year's data was recorded in three data files 
(Accident, Vehicle, and Person). Given, the Driver information was contained 
in the Person file, driver data was extracted into a separate Driver file to allow 
merging of data between 1993 and 2006.
Preparation o f Data for Merging
In preparation for merging yearly data together, consistent variable 
definitions were examined by year. As necessary, variable definitions were 
expanded to allow for definitions that changed across years. To be clear, 
variable elements were not changed, just the definition of a variable was 
expanded to allow the merging of data from all years available. For example, a 
variable that was originally coded with a one digit number, might have 
expanded into two digit coding, thus requiring us to expand the earlier 
definition to allow later years to reside under the same variable name.
Data Merge and Validation
After the all data variables were examined for consistency, the data 
merge began. Each component of the crash data level was combined into one 
yearly data set in three steps: first, variables from the accident file were added 
to the vehicle file to create a temporary Vehicle_Accident data file; second, 
variables from the driver file were added to the Vehicle_Accident file to create 
a temporary Vehicle_Accident_Driver file; third, variables from the
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Vehlcle_Accident_Driver file were added to the Person file to create the yearly 
data set. Next, all yearly data sets were merged into a master data set by 
sequential stacking starting with 1975 until a master dataset inclusive of all 
available years of FARS crash data (currently 1975 through 2006). Given 
collection of medication data by drug name began in 1993, data from 1993 - 
2006 was extracted from the master dataset to form the analysis dataset. To 
validate the data merge, frequency reports were run for several years on 
various yearly characteristics such as Total Fatal Crashes, Traffic Crash 
Victims -  Drivers, and Traffic Crash Victims -  Passengers. These frequency 
reports were then compared to pre-existing reports contained in the FARS 
encyclopedia (National Highway Traffic Safety Administration, 2007b). All 
comparisons yielded exact matches.
FARS Variables Used
For our analysis we used data from the FARS database from 1993 to 
2006. While fatal crash data has been recorded since 1975, more 
comprehensive collection of medication data began in 1993 allowing for 
analysis by medication type including benzodiazepines and opioid analgesics.
We used the following FARS data; age, sex, drug test results (blood or urine), 
alcohol tests results (blood), type of vehicle driven, and the drivers' past driving 
record. To eliminate the influence of alcohol on driver error, only those drivers 
with a confirmed blood alcohol concentration of zero were included in the 
analysis.
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Benzodiazepine Classification and Exposure
Twenty-two different generic benzodiazepines were recorded for one or 
more drivers in the sample. We classified benzodiazepines according to half- 
life duration. Typically, research has focused on grouping benzodiazepines 
into either short (< 24 hours) or long half-life (24 hours or more) groups. Given 
that approximately one third of short half-life benzodiazepines within our 
sample were those that are typically prescribed as an anesthetic for out-patient 
surgery (e.g., midazolam), we separated the short half-life category into a short 
and intermediate half-life groupings. Therefore, benzodiazepines were 
grouped as follows: < 6 hours were classified as short; > 6 but < 24 hours as 
intermediate; and > 24 hours as long. See Table 1 for benzodiazepines 
included in this analysis and the half-life classification assigned. Some 
benzodiazepines had overlapping half-life categories, for example tetrazepam 
(half-life range: 3-26). In such cases, these benzodiazepines were placed in 
the half-life grouping for which the majority of their range fell (therefore, 
tetrazepam was categorized as intermediate half-life). While there is 
pharmacodynamic variability within these classifications one main 
benzodiazepine accounted for most prescriptions in each category, therefore 
minimizing the possible effects of pharmacodynamic variation. For each driver, 
a maximum of three drug exposure results were provided (in no particular 
order). Given the limited number of drivers in the sample with just one 
benzodiazepine, we allowed each case to have more than one benzodiazepine 
as long as each benzodiazepine fell into the same half-life category. Therefore,
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exposure was measured as either: No benzodiazepines detected, short half- 
life benzodiazepines, intermediate half-life benzodiazepines, or long half-life 
benzodiazepines detected.
Opioid Analgesics Classification and Exposure
All medications captured in the FARS database were classified as either 
opiod positive or negative according to section 1308.12 of the U.S. Code of 
Federal Regulations (U.S.Department of Justice - Drug Enforcement 
Administration, 2007). A total of 11 different opioid based analgesic 
medications were recorded for one or more drivers. Opioid containing 
medications included in the FARS sample are usually prescribed to treat pain 
(e.g.. Codeine, Morphine), control heroin dependence (e.g.. Methadone), or 
relieve coughing (e.g., Hydrocodone). See Table 1 for opioids included in this 
analysis. A maximum of three medication serum analyses were available for 
each driver, but we only considered those who tested positive for one opioid 
based medication. To reduce the potential bias of multiple drugs in a driver’s 
system, those drivers with two or more positive results for opioid analgesics 
were excluded from the analysis.
Proxy Measures o f Responsibility  -  Unsafe Driver Actions
A FARS analyst uses the police officer’s crash narrative to determine 
the driver related factors for each crash (Blower, 1998). For every driver in the 
FARS database, up to three (four since 1997) driver-related factors are 
recorded. The majority of these driver-related factors (codes 20 -  59 inclusive) 
are considered unsafe driver actions (UDAs), that is, actions that contributed to
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the crash (e.g., improper lane changing). Drivers for whom no UDAs were 
specified were assumed to not have contributed to crash initiation. In this 
study, cases were drivers with at least one UDA recorded in relation to the 
crash (e.g., weaving), controls were drivers who had no UDAs recorded. The 
full list is displayed in Appendix A.
Daniel Blower, Director of the University of Michigan Transportation 
Research Institute Center for National Truck and Bus Statistics, writes that the 
use of UDAs is preferred to traffic violations as a method for understanding the 
relative contribution of different drivers to a crash (Blower, 1998). This is 
because police officers are less likely to lay a charge for a traffic violation due 
to insufficient legal proof and therefore the use of traffic violations will lead to 
an incomplete picture of crash causes. Further, not all contributing factors are 
chargeable offences. On the other hand, the crash narrative contained in the 
police report and the source for the FARs analysts’ UDA coding, allows the 
reporting officer to record their judgment therefore providing a more detailed 
picture of the factors contributing to the crash.
Further, Blower has tested the validity of the UDA coding by comparing 
crash configurations that allow inference of crash responsibility, such as head- 
on, rear-end, and opposite direction sideswipe collisions, with the UDAs 
reported in one truck and one passenger vehicle fatal vehicle crashes. Blower 
found that in crash types that strongly imply causation, the driver of the striking 
vehicle was assigned the majority of UDAs (Blower, 1998). Along with 
Blower’s studies, researchers have successfully used UDAs as a measure of
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“responsibility” (Perneger & Smith, 1991; Bédard & Meyers, 2004; Bédard et 
al., 2007). For example, Perneger used UDAs contained in the FARS dataset 
to demonstrate that driver errors often explain high rates of crash involvement 
and these driver errors were significantly associated with specific driver 
characteristics (alcohol for example) (Perneger et al., 1991).
Driver History
The FARS data set also includes variables containing the drivers’ past 
three-year driving records. As it is important to control for high risk driving 
habits, we included these data in our analysis. Driving record variables include: 
number of accidents (crashes), number of recorded convictions for driving 
while impaired (DWI; includes both alcohol and drugs), speeding convictions 
(going too fast or too slow), other harmful moving violation convictions, and 
license suspensions and revocations. We excluded drivers aged less than 20 
given that they would not have had sufficient opportunity (years) to acquire a 
driving history. Finally, we limited the vehicles included in our analyses to 
drivers of passenger vehicles, sport-utility vehicles and light trucks (pick-up 
trucks) only.
Analytical plan
Similar analyses plans were followed for both benzodiazepine and 
opioid analgesic medications. First, descriptive statistics were used to examine 
both demographic characteristics and most reported UDAs by benzodiazepine 
or opioid analgesic exposure groups. For benzodiazepines, exposure was 
categorized as follows: no benzodiazepines detected, short half-life
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benzodiazepines only, intermediate half-life benzodiazepines only, and long 
half-life benzodiazepines only. For opioid analgesics, exposure was 
categorized as either: no opioid analgesics detected or opioid analgesic 
detected. Demographic characteristics and unsafe driver actions were formally 
compared by both exposure categories (benzodiazepines by half-life and 
opioid analgesics by presence) to the referent group using the Pearson Chi- 
square test (sex, unsafe driver actions) and One-way Analysis of Variance 
(age).
The main analysis included several logistic regression models. We first 
examined the difference in UDAs reported by each exposure medication 
(benzodiazepines or opioid analgesics) without adjusting for other factors.
Next, we ran a model that included age, sex, prior driving record, other 
medications, and our exposure variable. Given that the relationship between a 
driver’s age and committing an UDA could be quadratic (i.e., curvilinear versus 
linear), we also included the quadratic age term. To examine the interaction 
between age, sex, other medications, and the exposure variable, the third 
model included all two-way and three-way interaction of these terms. Finally, 
the last model included significant two-way and three-way interaction terms 
from the third model and all other terms (exposure variable, age, sex, other 
medications, and driver history).
Logistic regression allows the calculation of predicted odds (PCs) and 
odds ratios (ORs). Essentially, PCs are the probability of an event happening 
divided by the probability of an event not happening for a given combination of
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explanatory variables. An odds ratio is the comparison by exposure of two 
POs. We used the logistic regression model to calculate POs of any UDA at 
selected combinations of the three interacting variables, and also calculate 
ORs of any UDA by benzodiazepine half-life and opioid analgesic exposure. 
Alpha was set at p<.05 and we report 95% confidence intervals. All analyses 
were done with SPSS version 15.
Results 
Benzodiazepines
Of the 72,026 drivers with a blood alcohol content of zero, 2,200 (3%) 
tested positive for any benzodiazepine. Of these 1,550 cases tested positive 
for one or more of the same half-life Benzodiazepines as follows: 161 Short 
half-life; 369 Intermediate half-life; 1,020 Long half-life. These cases were 
included in the analyses. An additional 465 drivers tested positive for 
benzodiazepines which were unclassified by half-life and another 185 drivers 
tested positive for multiple benzodiazepines classified in more than one half- 
life category. These cases were not included in the analyses. In general, 
drivers exposed to benzodiazepines were slightly younger than non exposed 
drivers, but had a similar ratio of male:female drivers, they also were more 
likely to be on another medication aside from benzodiazepines, and had a 
worse driving record than those drivers with no benzodiazepines detected. Full 
results are displayed in Table 2.
For those drivers taking benzodiazepines, the most frequently reported 
medication classes were: depressants, narcotics, stimulants, cannabinoids.
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and other (non FARS classified) drugs. Hallucinogens, PCP, steroids, and 
inhalants had the lowest reported prevalence. Overall, drivers taking 
benzodiazepines had higher positive test results for other medications than 
drivers with no benzodiazepines detected. Approximately one in six drivers 
(16.9%) with no benzodiazepines detected tested positive for another 
medication compared to 47%, 66%, and 58% of drivers taking short, 
intermediate, and long half-life benzodiazepines respectively.
The five most frequently reported UDAs by medication exposure group 
are reported in table 3. Overall, drivers exposed to either intermediate or long 
half-life benzodiazepines had an 11-14% higher reporting rate of any UDA 
compared to those not exposed. Specifically, there were significantly higher 
reports of “Failure to keep in proper lane/Running off road” and “Driving too 
fast” for those drivers’ taking intermediate and long half-life benzodiazepines 
compared to drivers with no benzodiazepines detected. Those on short half-life 
benzodiazepines had a similar reported rate of any UDA compared with drivers 
not exposed.
The crude ORs of any potentially unsafe driver action occurring were 
1.08 (95% 01=0.79, 1.49), 1.94 (95% Cl = 1.53, 2.46) and 1.66 (95% Cl =
1.45; 1.91 ) for those exposed to short, intermediate, and long half-life 
benzodiazepines respectively. After adjusting this association for age, sex, 
other medications, and driving record the ORs were 1.00 (95% 01=0.72, 1.39),
1.54 (95% 01 = 1.21,1.96), and 1.44 (95% 01 = 1.25; 1.66) for those exposed 
to short, intermediate, and long half-life benzodiazepines respectively. We next
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examined whether age, sex, and other medications (including depressants, 
narcotics, stimulants, cannabinoids, and other medications) interacted with 
benzodiazepine exposure. Sex did not significantly interact with the 
benzodiazepine exposure variable (Wald(3) = 5.0, p = .17) nor did the overall 
age term (Wald(3) = 5.0, p=.17). However, while age did not significantly 
interact with short (Wald(1) = .74, p = .39) or intermediate (Wald(1) = .34, p =
.56) half-life benzodiazepines, age did significantly interact with long half-life 
benzodiazepines (Wald(1) = 3.96, p = .047). Given this significant interaction 
and that we expected age may be related to the half-life duration of 
benzodiazepines, the age by benzodiazepine interaction was included in the 
final model. Of the five medication categories examined, none interacted 
significantly with benzodiazepines. Given the low reported prevalence of 
Hallucinogens, PCP, Steroids, and Inhalants, these were combined into the 
Other medications category in the final model. Therefore, the final model 
included benzodiazepine exposure, driver sex, driver age, the quadratic driver 
age term, benzodiazepine exposure by age interaction, sex by age interaction, 
other medications, and previous driving record variables. The final ORs of an 
UDA occurring when age was centered at 45 years were 1.02 (95% 01=0.73,
1.42), 1.53 (95% Cl = 1.20, 1.96) and 1.44 (95% Cl = 1.25; 1.66) for those 
exposed to short, intermediate, and long half-life benzodiazepines 
respectively.
Younger age, male sex, and poorer driving records were associated 
with a higher risk of a reported UDA. In particular, one or more of either
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“Previous Accidents” , “Previous Other Convictions”, or “Previous Speeding 
Convictions” increased the odds of an UDA by 15%, 11%, and 8% 
respectively. Linear increases were associated with reported UDAs for those 
with repeated offenses in the categories of “Previous Accidents” , “Previous 
Speeding Convictions”, and “Previous Suspensions”. For example, as the 
number of repeated “previous suspensions” increased (1 ,2 ,3  or more) so did 
the odds of a UDA (33%, 42%, and 58% respectively). See Table 4 for more 
detail.
To examine the possible age by benzodiazepine exposure interaction, 
we generated predicted odds and odds ratios for selected ages (every 10 
years, 25 through 75) (Aiken & West, 1991; Jaccard, 1998). These estimates 
show how the effects of benzodiazepines depend on age (see Figures 1, 2 and 
Table 5). For example, the odds ratio for a 25 year old driver using a long half- 
life benzodiazepine is 1.68 (95%: 1.34, 2.12) compared to 1.13 (95% Cl: 0.84;
1.53) for a 75 year old driver. Overall, drivers taking intermediate and long half- 
life benzodiazepines demonstrated increased odds of an UDA from ages 25 
(Intermediate OR: 1.59; 95% 01=1.08, 2.33; Long OR: 1.68; 95% 01=1.34,
2.12) to 55 (Intermediate OR: 1.50; 95% 01=1.09, 2.06; Long OR: 1.33; 95%
01=1.12, 1.57). As we can see from both Figures 1 and 2, younger drivers 
taking intermediate or long half-life benzodiazepines had the greatest 
increases in predicted odds and the largest odds ratios.
To further validate our analysis, we re-ran the final model (excluding 
any of the other medication terms), including only those cases that tested
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positive for just one benzodiazepine only or no medications at all.
Approximately 83% (N=58,562) of drivers not testing positive for 
benzodiazepines tested negative for other medications. Of those drivers 
testing positive for benzodiazepines, 53% of short (N=86), 32% (N=119) of 
intermediate, and 20% (N=200) of the long half-life cases were retained in the 
validation analysis. Similar trends were seen across benzodiazepine 
categories. While significance at the p=.05 level was not obtained for the 
intermediate half-life benzodiazepines (with the exception at age = 45, OR:
1.51, 95%CI: 1.02; 2.24) likely due to the much smaller sample size, a similar 
odds ratio pattern by age was demonstrated. For example, the odds ratio for 
those drivers taking intermediate half-life benzodiazepines ranged between 
1.59 for 25 year olds to 1.40 for 75 year olds. For those drivers taking long 
half-life benzodiazepines, the results paralleled the analysis which included 
drivers on other medications; statistically significant increased odds of an UDA 
were seen from ages 25 (OR: 1.69; 95%: 1.05, 2.71) to 55 (OR: 1.61 ; 95%
01=1.13, 2.30). See Table 6 for the full results.
Given that research has shown that time of day can influence results for 
older drivers, we re-ran our analyses including time of day using the same 
intervals as Ray (6am -  12 pm; 1 pm -  7 pm; 8 pm -  5 am) (Ray et al., 1992). 
While time of day contributed significantly to the model and interacted 




In total, 72,026 drivers tested for both alcohol and drugs had a blood 
alcohol content level of zero. Of these, 2,109 (3%) tested positive fo ra  single 
opioid analgesic (see Table 7) and form the basis of the analyses. An 
additional 380 (1%) cases tested positive for two opioid analgesics, and 
another 52 (0.2%) for three opioid analgesics; these cases were not included 
in the analyses. Regardless of medication status, drivers had a mean age of 
approximately 46 years of age and approximately two thirds were male. 
Approximately 60% of those drivers taking opioid analgesics were also taking 
at least one other medication compared to only 16% of those drivers testing 
negative for opioid analgesics. Depressants (27%), stimulants (16%), and 
cannabinoids (8%) were the most prevalent. Given that hallucinogens (.2%), 
PCP(.3%), and inhalants (0.05%) were the least prevalent medications these 
cases were combined with the other (non PARS classified) drug category with 
20% of drivers taking opioid analgesics who also tested positive for these other 
medications. Drivers who tested positive for opioid analgesics had a worse 
driving record (higher percentage with previous crashes, DWI convictions, 
other driving convictions, speeding infractions, and license suspensions). Full 
results are displayed in Table 8.
Table 9 displays the top five most frequently reported unsafe driver 
actions. The group of drivers taking opioid analgesics had a 16% higher 
proportion of any unsafe driver action reported compared to the group of 
drivers on no opioid analgesics, %^(1, N=71,592)= 86.2, p <.001. In particular.
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drivers using opioid analgesics had significantly higher reported frequencies 
than non-opioid analgesic drivers for the following unsafe driver actions:
“Failure to keep in proper lane” (41% greater, (1, N=71,592)= 147.6, p 
<.001 ); “Driving too fast” (13% greater, (1, N=71,592)= 4.1, p =.042);
“Making Improper Turns” (40% greater, (1, N=71,592)= 7.0, p =.008); and 
“Reckless vehicle operation” (20% greater, %^(1, N=71,592)= 6.8, p =.009).
While “Failure to properly yield” was the third highest unsafe driver action 
reported for those taking opioid analgesics it had a significantly lower reported 
frequency compared to those drivers on no opioid analgesics (33% less, (1, 
N=71,592)= 27.9, p <.001 ).
Testing positive for the presence of an opioid analgesic increased the 
risk of performing an unsafe driver action by 57% (Unadjusted OR: 1.57;
95%CI: 1.43; 1.73). After adjusting this association for age, sex, other 
medications, and driving record the OR was 1.30 (95% Cl = 1.18; 1.44). We 
next examined whether age, sex, and other medications interacted with opioid 
analgesic exposure. Sex (Wald Statistic = 4.8, p = .028), stimulants (Wald 
Statistic = 10.8, p = .001), and depressants (Wald Statistic = 5.0, p = .025) 
interacted significantly with the opioid analgesic exposure variable and were 
therefore retained in the final model. Given the quadratic age term interaction 
approached significance (Wald Statistic = 3.5, p = .061), we also included the 
age by opioid analgesics exposure and quadratic age by opioid analgesics 
exposure in the final model. Therefore, the final model included opioid 
analgesic exposure, driver sex, driver age, the quadratic driver age term.
The Impact 54
opioid analgesic exposure by age interaction, opioid analgesics by age 
squared interaction, opioid analgesic exposure by stimulant medication 
interaction, opioid analgesic exposure by depressant medication interaction, 
opioid analgesic exposure by sex interaction, sex by age interaction, sex by 
age squared interaction, other medication, and previous driving record 
variables. The final ORs of an UDA occurring when age was centered at 45 
years was 1.72 (95% Cl = 1.45; 2.03) for those exposed to opioid analgesics.
Younger age, male sex, testing positive for other medications, and 
poorer driving records were associated with higher odds of a reported UDA.
Risk was increased for those also testing positive for other medications with 
the exception of Narcotics. For each of the previous driver history variables, 
linear increases were associated with higher odds. For example, as the 
number of repeated offenses increased (1 ,2 ,3  or more) so did the odds of an 
unsafe driver action. Those drivers with “Previous Suspensions” had the 
greatest increased risk (33%, 38%, and 56% respectively). See Table 10 for 
more detail.
Given the significance levels in the final model for both the sex by opioid 
analgesic exposure term (Wald = 4.04, p = .045) and the quadratic age by 
opioid analgesic exposure term (Wald = 3.20, p = .074) in the final model, we 
generated predicted odds and odds ratios for selected ages (every 10 years,
25 through 75) by sex (Aiken et al., 1991; Jaccard, 1998). These estimates 
show how the effects of opioid analgesic depend on both age and sex (see 
Figures 3,4 and Table 11 ). For example, the odds ratio for a 25 year old using
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an opioid analgesic, was 1.35 (95%: 1.05, 1.74) for a female driver, and 1.66 
(95% Cl: 1.32; 2.09) for a male driver. In comparison, at 75 years old the odds 
ratios were 0.94 (95% 01: 0.73; 1.22) for a female driver and 1.15 (95% 01:
0.91 ; 1.47) for a male driver. As can be seen in Figure 2, younger and middle- 
aged male drivers taking opioid analgesics had the greatest increases in 
predicted odds and the largest odds ratios.
To validate our analysis, we re-ran the final model, deselecting any 
case that had tested positive for any other medication. Included were 840 
drivers from the opioid analgesic group and 58,549 drivers from the non opioid 
analgesic group. Similar patterns were seen to the analysis including drivers 
on other medications. For example, female drivers had significantly increased 
odd of an unsafe driver action from age 25 (OR: 1.69; 95% 01: 1.17; 2.44) 
through 55 (OR: 1.27; 95% 01: 1.12; 1.68). Male drivers had significantly 
increased odds of an unsafe driver action from age 25 (OR: 1.76; 95% 01:
1.27; 2.44) through age 65 (OR: 1.32; 95% 01: 1.04; 1.68). See Table 12 for all 
results. Regardless of sex, the highest odds ratios were seen at age 35 in both 
the original and validation analysis.
Discussion 
Benzodiazepines
Depending on the age of the driver and type of medication exposure 
(benzodiazepine by half-life or opioid analgesic) the odds of an UDA increased 
by similar levels, 33% to 68% for drivers taking benzodiazepines, and 30% to
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70% for drivers taking opioid analgesics compared to the respective control 
group drivers. In both medications’ analyses, younger and middle age drivers 
were at the most risk. For example, drivers aged 25 had the highest odds of 
committing an UDA when exposed to either intermediate or long half-life 
benzodiazepines.
Effects o f Age
The impact of benzodiazepines decreased with age but remained 
statistically significant for intermediate and long half-life benzodiazepines 
through middle age. Interestingly, benzodiazepine exposure did not 
significantly increase the odds of an UDA for drivers aged 65 and older which 
at first can appear counter to both Ray and Hemmelgarn’s findings (Ray et al., 
1992; Hemmelgarn et al., 1997). As Ray demonstrated, part of this may be 
explained by driver behavior. Ray’s study showed that drivers 65 and older 
who were taking benzodiazepines (only) were at increased risk between the 
hours of 6 am and 12 pm (Relative Risk = 2.0, 95% Cl: 1.3, 3.2) but not 
between 1 pm and 7 pm or 8 pm and 5 am (Ray et al., 1992).
It is also possible that our benzodiazepine analyses lacked sufficient 
statistical power for drivers 65 and older. Hemmelgarn and colleagues did not 
find increased risk for benzodiazepines with a half-life less than 24 hours, 
which is equivalent to our findings. However, they found that odds were 
increased for those taking long half-life benzodiazepines (Adjusted OR: 1.28,
95% Cl: 1.12, 1.45). Our adjusted ORs are similar to those reported by 
Hemmelgarn (Adjusted OR for 65 year old: 1.22, 95% Cl: 0.98; 1.54). Given
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that we examined fatal crashes only and not those crashes resulting in non- 
fatal injuries, our sample of 205 drivers aged 65 and older exposed to 
benzodiazepines was considerably smaller than the 6,064 benzodiazepine 
exposed cases in Hemmelgarn’s study and the 2,978 cases in Ray’s study 
(Hemmelgarn et al., 1997; Ray et al., 1992).
Short Benzodiazepines
Drivers taking short half-life benzodiazepines (classified as <6 hour half- 
life), did not demonstrate increase odds of an unsafe driver action. This may 
be due to the fact that these medications are generally used for anesthesia in 
outpatient surgery and not to relieve anxiety or to aid sleep. One assumes that 
drivers would be warned about the possible side effects, post surgery, of the 
short benzodiazepines and therefore, if they still chose to drive, would 
demonstrate more vigilance than normal. Further, given this group’s short half- 
life, the effects would most likely be minimal within a few hours after surgery. 
Interestingly, our overall results are similar to the dose-response results found 
in Barbone’s study who also examined benzodiazepines by half-life (short: < 6 
hours, intermediate: 6-24 hours, and long: > 24 hours) and found that 
intermediate and long half-life benzodiazepines significantly increased the 
odds of a crash but short benzodiazepines did not (Barbone et al., 1998).
Driver Behavior
The higher odds of an UDA with intermediate and long-acting 
benzodiazepines may be explained by the effect of these medications on 
driver behavior. Failure to stay in the proper lane was the number one UDA
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across exposure categories. These results were especially prominent in the 
intermediate and long half-life benzodiazepines driver group who had 
approximately fifty percent more proportional cases cited for this particular 
unsafe driving action compared to drivers with no detected medications.
Driving too fast was the second highest UDA cited for the intermediate and 
long half-life group. When compared with the non benzodiazepine group, the 
intermediate and long groups had 38% and 25% higher proportion of drivers 
cited respectively for this UDA. These results mirror experimental studies 
demonstrating that benzodiazepines significantly impair control of lateral 
position (i.e., weaving) and affect speed perception (O'Hanlon, Haak, Blaauw,
& Riemersma, 1982; van Laar et al., 1992; Irving & Jones, 1992).
Opioid Anaigesics
To date, epidemiological literature has focused on using prevalence 
rates to demonstrate minimal, or no associations between the use of opioid 
analgesics and safe driving. While prevalence rates remain relatively low in 
traffic crashes, the contribution of opioid analgesics to unsafe driver actions in 
fatal traffic crashes appears much greater than expected. Compared to drivers 
on no medications, those drivers testing positive for an opioid analgesic had 
the odds of an unsafe driver action increased by 30% to 74% depending on 
the driver’s age and sex.
Effects o f Age
While younger and middle-aged drivers had the highest odds of 
committing an unsafe driver action when exposed to opioid analgesics.
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significantly increased odds were seen at all of the selected ages except 65 
and 75 for females, and 75 for males. It should be noted that regardless of 
medication status, the predicted odds of an unsafe driver action aged 75 were 
2.15 for females and 2.21 for males, among the highest of all age categories. 
Given that the predicted odds for drivers with no medication detected, aged 75, 
was 2.28 in females and 1.92 in males, the odds ratios were not significant.
Driver Behavior
The possible effects of opioid analgesics on driver behavior may explain 
the significantly higher odds of an unsafe driver action. The opioid analgesic 
group had a 16% greater proportion of reported UDAs compared to the no 
medication detected group. Of the Top 5 unsafe driver actions committed by 
drivers taking opioid analgesics, four were reported in significantly higher 
proportions when compared to drivers with no medication detected. The 
second, fourth, and fifth highest unsafe driver actions cited were: driving too 
fast for conditions; making improper turns; and erratic, reckless, careless or 
negligent vehicle operation respectively. Approximately 18% of drivers were 
cited for driving too fast, seven percent for improper turns, and six percent for 
erratic or reckless vehicle operation. While these proportional differences were 
similar to non opioid analgesics group, the differences were statistically 
significant. Of the top 5 unsafe driver actions reported for drivers on opioid 
analgesics, only failure to yield right of way, obey signs or other safety zone 
traffic laws was significantly lower than the non opioid analgesic drivers. Nearly
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a 33% higher proportion of the non opioid analgesic drivers were cited for this 
unsafe driver action.
Failure to keep in the proper lane was the number one unsafe driver 
action reported for drivers taking opioid analgesics. Two of every five drivers 
were cited, approximately a 41% higher proportion cited compared to the no 
opioid analgesics detected group. Examples of failure to keep in proper lane 
include the vehicle crossing the centerline or the vehicle going straight in a turn 
lane (Tessmer, 2007). While minimal differences were found in the 
experimental literature between opioid analgesic drivers and non-medicated 
drivers, Byas-Smith found visual information was processed at half the speed 
of healthy normals, and Galski found twice as many visual scanning errors 
compared to the their cerebrally compromised control group (Byas-Smith et al., 
2005; Galski et al., 2000).
Driving Record
Of interest, we found that drivers taking opioid analgesics had a poorer 
driving record compared to the non-medicated control group. In 2003, Fishbain 
after reviewing the current literature concluded, “that there was strong, 
consistent evidence for no greater incidence in motor vehicle violations/motor 
vehicle accidents versus comparable controls of opioid-maintained patients” 
(Fishbain, Cutler, Rosomoff, & Rosomoff, 2003). Our results demonstrated 
large, statistically significant, proportional differences in both categories. In 
terms of previous motor vehicle crashes, the opioid analgesic group had a 
32% higher proportional number of previous crashes in the past three years
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compared to the non opioid analgesic control group. In regard to the poorer 
driving record, those on opioid analgesics had a 38% higher proportional 
number of other traffic convictions, 12% higher proportional number of 
speeding violations, and 88% proportionally higher number of license 
suspensions in the past three years compared to the non opioid analgesic 
control group.
All Medications
Predicted Odds at Cider Ages
Another important consideration when interpreting the study results is 
the possibility that the lower odds ratios for the older age groups may be due 
to the increased odds of an UDA for non-exposed drivers and not necessarily 
the decreased odds for exposed drivers. In Figures 2 and 4, we clearly see the 
well known u-shaped crash risk by age relationship in the drivers with no 
medications detected (McGwin, Jr. & Brown, 1999; Tay, 2006). Both younger 
and older drivers are at higher risk regardless of medication status. For 
example, while the predicted odds of an UDA for drivers aged 75 exposed to 
intermediate half-life benzodiazepines was 2.73, higher than any other age 
category for intermediate half-life benzodiazepines, the odds ratio was not 
significant given that for drivers with no medications detected, aged 75, the 




Marker o f Exposure
Our study has some important limitations. Our marker of exposure is 
dichotomous (present/absent) and therefore we do not know the route of 
administration, blood concentration level at time of crash, dosage received, or 
current dosing regime -  all of which could influence this study's findings.
Taking blood concentration as an example of this limitation, some drivers may 
have tested positive for either of these medications but have low 
concentrations that would not be expected to impair driving. The main 
consequence of this limitation is the potential underestimation of the risk posed 
by the benzodiazepine or opioid analgesic. Another example of this limitation is 
seen when considering dosing regimes for those taking opioid analgesics. 
Considering the literature, (Bruera et al., 1989; Galski et al., 2000; Vainio et al., 
1995; Byas-Smith et al., 2005; Gaertner et al., 2006) we would expect those 
on stable dosing regimes on opioid analgesics to be safer drivers. If our 
sample consists of mainly those on stable dosing, then our results would 
represent an under-estimate of the potential risk associated with driving and 
non-stable opioid analgesic use. Conversely, if our sample had a higher 
proportion of drivers on a new dosing regime the results of the study would be 
an over-estimate of the associated risk of driving and stable opioid analgesic 
use. A similar bias could be seen with benzodiazepines. In terms of 
benzodiazepine use, experimental studies demonstrate that longer duration of 
use can reduce the adverse effects on driving performance as tolerance
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increases. Therefore, this may lead to an underestimation of the increased 
risks for those beginning a new benzodiazepine prescription but an 
overestimation for long-term users.
Detection Methods
There is another important limitation of our study that needs to be 
considered especially given that the marker of exposure is dichotomous. The 
PARS database includes cases for all of the United States. Given that testing 
methods are determined at the state level we cannot comment on the 
accuracy of the tests and the possibility of bias introduced by test variation. 
Further, as the PARS data used in this study were collected every year since 
1993, it is also possible that detection methods have become more sensitive 
over time. This may have introduced two sources of error. First, tests from 
earlier years may have less sensitivity (than recent ones) resulting in the 
classification of users of benzodiazepines or opioid analgesics as non-users; 
this would lead to an underestimation of the impairment effects of these 
medications. Second, newer testing methods may potentially result in the 
detection of traces of medications that would not necessarily be enough to 
result in driver impairment; this could lead to an under estimation of the effect 
of benzodiazepines and opioid analgesics.
Medical Conditions
Another limitation is that we do not know what medical conditions the 
benzodiazepines or opioid analgesics were prescribed for. It is possible that 
these medical conditions (e.g., cancer) and their symptoms (such as the pain
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itself) are the causal agent for the impairment. For example, Sagberg 
examined the relative crash risk of involvement associated with various 
medical conditions. He demonstrated that at fault drivers who self-reported 
sleep onset insomnia, tiredness, and anxiety had increased odds of being at 
fault for a crash (OR = 1.87, p<.01; OR = 1.36, p = .03; OR = 3.15, p = .03 
respectively) when controlling for age and annual driving distance compared 
with drivers without the particular medical condition (Sagberg, 2006). However, 
Sagberg reports that it is unclear as to whether medications may have been 
used during the time of the crash (Sagberg, 2006).
Sagberg also examined relative crash involvement risk associated with 
musculoskeletal and pain related conditions. Controlling for age and annual 
driving distance, Sagberg found no significantly increased odds of being at 
fault for a crash compared with those drivers without the particular medical 
condition or medication during the study time period (Sagberg, 2006). In 2006, 
Veldhuijzen examined the effect of chronic nonmalignant pain on highway 
driving performance (Veldhuijzen et al., 2006). Their study used both on-road 
and psychometric testing to measure driving performance differences between 
14 chronic nonmalignant pain patients (not on medication) with 14 healthy 
controls. The primary outcome of the on-road test was standard deviation of 
lateral position (SDLP, i.e., the amount of weaving of the car within the traffic 
lane), which was measured continuously over a 100 km highway course.
Drivers suffering from chronic nonmalignant pain performed worse than the 
healthy controls, having an approximately 20% higher mean SDLP. The
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authors found a statistically significant group effect (p = .007) between the pain 
group and healthy controls. No statistical differences were found on mean 
speed, standard deviation of speed, or mean lateral position. Of interest, pain 
intensity and SDLP were not found to significantly correlate though this may be 
due to the small sample size. Further, while drivers suffering from pain did not 
score significantly different compared to the healthy controls, the direction of 
certain psychometric tests (measuring motor coordination, reaction, and 
divided attention) appeared worse than the healthy controls.
Charlton and colleagues examined the influence of chronic illness on 
crash involvement of motor vehicle drivers, including anxiety disorders 
(Charlton et al., 2004). Individuals with anxiety disorders can demonstrate a 
heightened alertness to threat and a tendency to worry which can have the 
adverse effects related to driving function including: decreasing working 
memory, increased distraction, and less attentional capacity available 
(Charlton et al., 2004). Further, the presence of chronic illness and co­
morbidities increases the potential for polypharmaceutical effects. However, 
we did control for the influence and tested for possible interactions of 
medications that may contribute to impairment such as depressants, narcotics, 
and cannabinoids.
Enhancing Agents
While the FARS database screens for medications that have possible 
impairing effects such as narcotics, depressants, and hallucinogens it does not 
classify (but instead places them in a general other category) all medications
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that may impair drivers or medications that may enhance the impairment 
effects of benzodiazepines or opioid analgesics. For example, omeprazole, a 
drug frequently used to treat ulcers and gastroesophageal reflux disease, is 
known to significantly reduce the elimination of certain benzodiazepines such 
as diazepam, potentially resulting in further impairment (Holt & Howden, 1991 ).
Possible Selection Bias
There is also the potential of selection bias in our sample. Of the 
147,582 drivers between 1993 and 2006 with a blood alcohol level equal to 
zero, we analyzed only the 72,026 (49%) who were tested for drug use. This 
leaves 75,556 (51%) drivers who were not given a drug test. It is possible that 
several of these cases were taking benzodiazepines or opioid analgesics but 
their driving behavior did not warrant a drug test. If this is the case, including 
these cases would reduce the estimated risk posed by benzodiazepines and 
opioid analgesics.
Study Strengths
Some strengths of the study are worth noting. The use of unsafe driver 
actions as a proxy measure for crash initiation provides a better assessment of 
the putative causal relationship between benzodiazepines, opioid analgesics, 
and safe driving. Controlling for previous driver record and the driver’s age and 
sex is a strength of the study, especially given the driving record differences 
found between medicated and non-medicated groups. Unlike many 
epidemiological studies, our sample had a relatively good proportional sex 
representation, with approximately 40% of drivers being female and also
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contained drivers from all age groups. Given the size of our sample, we were 
also able to eliminate any drivers that tested positive for alcohol (a BAG > 0), 
thereby ruling out the effects of alcohol. Further, in the validation analysis, we 
isolated cases that tested positive for only one opioid analgesic or one 
benzodiazepine and no other medications, removing possible associations 
influenced by multiple medications or medications and alcohol.
Concluding Remarks
By using a proxy measure for crash initiation, moderating for driver 
characteristics such as age, sex, and driving record, and excluding drivers 
under the influence of alcohol or other medications, the results of our study, 
which suggest that benzodiazepines and opioid analgesics negatively affect 
safe driving, add to the current evidence.
For benzodiazepines, our results complement both the epidemiologic 
and experimental literature. Given the growing evidence regarding 
benzodiazepines and safe driving, the American Medical Association (AMA) 
recommends that patients of all ages be prescribed the shortest-acting 
benzodiazepine appropriate for their condition (Wang, Kosinski, Schwartzberg,
& Shanklin, 2003). Those requiring longer-acting benzodiazepines should be 
advised of the possible impairment and associated risks while driving. 
Additionally, the AMA recommends that these patients should be advised to 
avoid driving, particularly during the initial phase of dosing (or adjustment)
(Wang et al., 2003).
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In terms of opioid analgesics, to date, there is limited evidence 
suggesting that opioid analgesics negatively affect safe driving. Nevertheless, 
given the potential side effects that may impair driving, the American Chronic 
Pain Association recommends warning the patient (and family of) against 
driving until a tolerance or baseline is reached (Covington, 2007). Brandman 
provides excellent suggested guidelines to optimize driving safety for the 
family physician, patient, and their family including driver safety vigilance, 
examining the possibility of outside help (e.g., other drivers might be available 
if the patient should not drive), and recognizing that certain accommodations 
(such as changing driver habits) will be necessary while under the influence of 
opioid analgesic medications (Brandman, 2005).
For both classes of medications, further work to clarify the specific 
nature of their impact on driving is required. Research to determine how the 
course of therapy (early on, long term), for each medication, influences the 
impact on driving would be beneficial. However, development of these 
medications should also continue, not only to increase their efficacy but also to 




Table 1: Benzodiazepines by half-life included in analysis (Adapted from: 
Ashton, 2007; BCNC, 2007)
Half-Life
Cateqorv
Generic Name Half-Life (Hours) N (%) 
(active metabolite]
Short Half-Life
Midazolam 1.8 -6 159 (98.8%)




Alprazolam 6-12 297 (80.5%)
Bromazepam 10-20 1 (0.3%)
Clotiazepam 6-17 1 (0.3%)
Estazolam 10-24 2 (0.5%)
Loprazolam 6-12 2 (0.5%)
Lorazepam 10-20 16 (4.3%)
Lormetazepam 10-12 2 (0.5%)
Oxazepam 4-15 14 (3.8%)
Temazepam 8-22 45 (12.2%)
Tetrazepam 3-26 1 (0.3%)
Total* 369*
Lonq Half-Life
Chlordiazepoxide 5-30 [36-200] 51 (5.0%)
Clobazam 12-60 2 (0.2%)
Clonazepam 18-50 15(1.5%)
Delorazepam 60-200 3 (0.3%)
Diazepam 20-100 [36-200] 815 (79.9%)
Flurazepam [40-250] 3 (0.3%)
Ketazolam 30-100 [36-200] 3 (0.3%)
Nitrazepam 15-38 1 (0.1%)
Nordiazepam 36-200 583 (57.2%)
Prazepam [36-200] 1 (0.1%)
Total* 1,020*
* Given some cases may have multiple BZDs per half-life category, totals 
indicates total number of cases with one or more of the particular half-life 
category.













X '/F  ** p Value
Age, mean (SD), year 46.0 (19.3) 43.2(18.4) 42.3(15.6) 44.0 (16.3) 9.3 <001
Male, # (%)*** 45,235 (64.8) 107 (66.5) 233 (63.1) 638 (62.5) 2.9 .415
Other Medications
Depressant, # (%) 759 (1.1) 5(3.1) 30 (8.1) 101 (9.9) 777.2 <.001
Narcotic, # (%) 2,150 (3.1) 14(8.7) 117(31.7) 224 (22.0) 1942.8 <.001
Stimulant, # (%) 3,842 (5.5) 16(9.9) 75 (20.3) 131 (12.8) 254.4 <001
Cannabinoid, # (%) 2,689 (3.9) 9 (5.6) 33 (8.9) 66 (6.5) 44.4 <.001
Other Medications, # (%) 4,028 (5.8) 44 (27.3) 52(14.1) 171 (16.8) 387.8 <.001
Any Other Medication, # (%) 11,270(16.1) 75 (46.6) 245 (66.4) 589 (57.7) 1968.6 <.001
Driving Record -
One or more in the past three years
Crashes, # (%) 10,165(14.6) 14 (8.7) 78 (21.1) 213(20.9) 49.1 <.001
DWI, # (%) 1,164 (1.7) 5(3.1) 30 (8.1) 81 (7.9) 310.9 <.001
Other Conviction, # (%) 10,933(15.7) 26(16.1) 107 (29.0) 191 (18.7) 56.0 <.001
Speeding, # (%) 13,173(18.9) 39 (24.2) 113(30.6) 204 (20.0) 36.7 <.001
Lie. suspension, # (%) 6,912(9.9) 17(10.6) 79 (21.4) 195(19.1) 146.6 <.001
Any of the above, # (%) 27,322 (39.1) 68 (42.2) 218(59.1) 506 (49.6) 107.1 <.001


















Failure to keep in proper lane, # (%) 20,146 (29%) 58 (36%) 154 (42%) 445 (44%) 138.5 <001
Driving too fast for conditions or in excess of 
posted maximum, # (%)
11,267 (16%) 18(11%) 81 (22%) 209 (20%) 26.0 <001
Failure to yield right of way, obey signs or
other safety zone traffic laws, # (%)
11,328 (16%) 35 (22%) 38(10%) 113(11%) 32.7 <.001
Making improper turn, # (%) 3,726 (5%) 1 (1%) 11 (3%) 45 (4%) 12.8 .005
Erratic, reckless, careless or negligent vehicle 
operation, # (%)
3,428 (5%) 5 (3%) 29 (8%) 53 (5%) 8.2 .044






Table 4; Odds Ratios with 95% Cl for the final model predicting Unsafe Driver Actions*




Age X  Sex
Depressants, none detected 
Narcotics, none detected 
Stimulants, none detected 
Cannabinoids, none detected 
Other Medications, none detected
Benzodiazepine Exposure, no 
benzodiazepines detected* 
Benzodiazepine Exposure by Age 
Interaction, no benzodiazepines 
detected
1.06(1.03; 1.10) 
0.44 (0.42; 0.47) 
1.00 ( 1.00 ;1.00) 
1.05 (1.03;1.07)
2.03 (1.73; 2.38) 
1.34(1.22, 1.46) 
2.34 (2.20,2.57) 
1.11 ( 1.02 ,1.21) 
1.15(1.08,1.23)
Short Intermediate
1.02 (0.73; 1.42) 1.53(1.20; 1.96)




Prior Driving Record 1 2 3 or more
Accident, none 1.15 (1.1;1.2) 1.35 (1.2;1.5) 1.46(1.2:1.8)
DWI, none 1.01 (0.9; 1.2) 1.15(0.8:1.7) 0.55 (0.2;1.4)
Other, none 1.11 (1.1;1.2) 1.16(1.1:1.3) 1.21 (1.1;1.4)
Speeding, none 1.08 (1.0;1.1) 1.13(1.0:1.2) 1.26(1.1:1.4)
Suspensions, none 1.33 (1.2:1.4) 1.42(1.3:1.6) 1.58(1.4:1.8)





Table 5: Adjusted odds ratios of any UDA by Benzodiazepine exposure and driver age
(No benzodiazepines detected is the reference category)
Exposure Age
25 35 45 55 65 75
Short 
(95% Cl) 0.87 (0.55:1.37) 0.94 (0.66:1.34) 1.02 (0.73:1.42) 1.11 (0.73:1.67) 1.20 (0.70:2.08) 1.31 (0.64:2.66)
Intermediate 
(95% Cl) 1.59 (1.08:2.33)* 1.56 (1.18:2.06)** 1.53 (1.20:1.96)*** 1.50 (1.09:2.06)** 1.47 (0.95:2.29) 1.44 (0.81:2.59)
Long 
(95% Cl) 1.68(1.34:2.12)*** 1.55 (1.31:1.84)*** 1.44 (1.24:1.66)*** 1.33(1.12:1.57)*** 1.22 (0.98:1.54) 1.13(0.84:1.53)
Note: Wald statistics are significant at the: 
* p<.05 level
p <.01 level 







Table 6: Validation Analysis: Adjusted odds ratios of any UDA by Benzodiazepine exposure and driver age
(No medications detected is the reference category)
Exposure Age
25 35 45 55 65 75
Short 
(95% Cl) 0.75 (0.41 ;1.37) 0.91 (0.57:1.45) 1.10(0.69:1.73) 1.32 (0.74:2.35) 1.59 (0.74:3.42) 1.92 (0.72:5.14)
Intermediate 
(95% Cl) 1.59 (0.86:2.95) 1.55 (0.98:2.46) 1.51 (1.02:2.24)** 1.48 (0.93:2.35) 1.44 (0.77:2.69) 1.40 (0.62:3.20)
Long 




(1.20:2.23)*** 1.61 (1.13:2.30)*** 1.59 (1.00:2.54)* 1.57 (0.85:2.89)
Note: Wald statistics are significant at the: 











Figure 1: Predicted Odds of an Unsafe Driver Action by Benzodiazepine exposure and driver age, with all
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Figure 2: Odds ratios of an Unsafe Driver Action by Benzodiazepine exposure by driver age, with all other
variables set to their reference categories
Legend
30H I  Short: 95% Cl
I  Intermediate: 95% 01 
Long: 95% 01














A g e (D
3“DQ)O
The Impact 78
Table 7: Opioid Analgesic medications detected
Generic Name Frequency of Opioid Analgesic Medications 
Detected










Hydrocodone 360(17.1%) 118(15.5%) 18(11.5% ) 496 (16.4%)
Methadone 371 (17.6%) 79 (10.4%) 16(10.3% ) 466 (15.4%)
Opium 256(12.1%) 89(11.7% ) 19(12.2% ) 364(12.0% )
Codeine 142 (6.7%) 124(16.3%) 35 (22.4%) 301 (10.0%)
Propoxyphene 257(12.2%) 33 (4.3%) 5 (3.2%) 295 (9.8%)
Oxycodone 136(6.4%) 67 (8.8%) 14 (9.0%) 217(7.2% )
Acetom inephen p lus Codeine 107 (5.1%) 29 (3.8%) 6 (3.8%) 142 (4.7%)
M eperidine 062 (2.9%) 16(2.1%) 2 (1.3%) 80 (2.6%)
O xym orphone 14 (0.7%) 10(1.3%) 2 (1.3%) 26 (0.9%)
H ydrom orphone 5 (0.2%) 12(1.6%) 2(1.3% ) 19(0.6%)
B utorphanol 1 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
Levorphanoi 1 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
Pentazocine 4 (0.2%) 0 (0.0%) 0 (0.0%) 4(0.1% )
Totai 2,109(100%) 760 (100%) 156 (100%) 3,025 (100%)
Totai Cases 2,109 (100%) 380 (100%) 52 (100%) 2,541 (100%)
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Table 8: Descriptive statistics for drivers tested for Opioid Analgesics








(N = 2,109) %2/t p-value
Age, Mean (SD ),years 45.9  (19.3) 45.7  (16.5) 0.4 .672
Male, N um ber (% ) 45,030 (64.8% ) 1 ,3 1 4 (6 2 .3 % ) 5.7 .017
Other Medications
Depressant, #  (% ) 2 ,300 (3.3) 575 (27.3) 3,047.1 <.001
Narcotic, #  (%) 194 (0.3) 51 (2.4) 274.6 <.001
Stim ulant, #  (% ) 3,811 (5.5) 3 2 9 (1 5 .6 ) 384.4 < 0 0 1
C annabinoid, #  (%) 2 ,7 1 5 (3 .9 ) 161 (7.6) 73.7 <.001
O ther M edications, #  (%) 3,868 (5.6) 421(20.0 ) 753.2 <.001
A ny O ther M edication, #  (% ) 10 ,936 (1 5 .7 ) 1,269 (60.2) 2 ,857.6 <.001
Driving Record -  One or more in the past three years
Crashes, No. (% ) 10 ,096 (1 4 .5% ) 402 (19.1% ) 33.6 <.001
DWI , No. (%) 1 ,202 (1 .7 % ) 93 (4.4% ) 828 . <.001
O ther Conv. , No. (% ) 10,859 (15.6% ) 455 (21.6% ) 54.4 <.001
Speeding , No. (% ) 1 3 ,135 (1 8 .9% ) 444 (21.1% ) 6.2 .013
Lie. Susp., No. (%) 6,847 (9.9% ) 393 (18.6% ) 173.6 < 001
Any o f the  above , No. (% ) 27,207 (39.2% ) 1,021 (48.4% ) 73.4 <.001
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Failure to keep in proper lane, #  (%) 20,046 (29% ) 866 (41% ) 147.6 <.001
Driving too fast fo r cond itions or in
excess o f posted m axim um , # 
(% )
11,270 (16% ) 3 7 7 (1 8 % ) 4.1 .042
Failure to yie ld righ t o f way, obey signs 
or o the r sa fe ty zone tra ffic .law s, #  
(% )
11,283 (16% ) 252 (12% ) 27,9 <.001
Making im proper turn, #  (%) 3,637 (5%) 138 (7% ) 7.0 .008
Erratic, reckless, care less o r neg ligent 
veh ic le  operation , #  (%)
3 ,4 1 2 (5 % ) 130 (6% ) 6.8 .009
Any UDA reported, #  (%) 42,758 (62% ) 1,508 (72% ) 86.2 <.001
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Table 10: Odds Ratios with 95% Cl for the final model predicting Unsafe
Driver Actions*











1.01 (1.01; 1.15) 
0.96 (0.95; 0.97) 
1.10 (1.09; 1.10) 
1.06(1.04; 1.08) 
0.99 (0.98; 1.00) 
1.05 (0.80; 1.39) 
2.41 (2.22; 2.62) 
1.10(1.01; 1.20) 
1.81 (1.64; 2.00) 
1.14(1.06; 1.22)
Opioid Analgesic
Opioid Analgesic Exposure, no 
opioid analgesic detected*
Opioid Analgesic Exposure by Sex 
Interaction, no opioid analgesic 
detected
Opioid Analgesic Exposure by Age 
Interaction, no opioid analgesic 
detected
Opioid Analgesic Exposure by 
Age^ Interaction, no opioid 
analgesic detected 
Opioid Analgesic Exposure by 
Stimulant Interaction, no opioid 
analgesic detected 
Opioid Analgesic Exposure by 
Depressant Interaction, no opioid 
analgesic detected






Prior Driving Record 1 2 3 or more
Accident, none 1.15(1.10;1.21) 1.34(1.20; 1.50) 1.45 (1.17; 1.79)
Other, none 1.11 (1.05; 1.16) 1.15 (1.05; 1.27) 1.20(1.05; 1.38)
Speeding, none 1.08 (1.03; 1.13) 1.12 (1.03; 1.22) 1.26 (1.12; 1.42)
Suspensions, none 1.33(1.24; 1.44) 1.38 (1.23; 1.55) 1.56 (1.38; 1.76)
DWI, none 1.04 (0.90; 1.20) 1.13 (0.77; 1.65) 0.55 (0.22; 1.35)
*Age centered at 45 years
Table 11: Predicted odds and adjusted odds ratios of any Unsafe Driver Action by Opioid Analgesic
exposure, driver age, and sex
Female Drivers Male Drivers
Predicted Odds
Odds Ratio (95% Cl)
Predicted Odds











25 1.43 1.94 1.35(1.05:1.73)* 1.51 2.51 1.66 (1.32:2.09)***
35 1.14 1.62 1.42 (1.17:1.72)*** 1.11 1.92 1.74(1.47:2.05)***
45 1.06 1.49 1.40(1.15:1.70)*** 0.97 1.66 1.72(1.45:2.03)***
55 1.17 1.52 1.30(1.07:1.58)** 1.01 1.62 1.59 (1.34:1.90)***
65 1.51 1.72 1.14(0.93:1.39) 1.28 1.78 1.40 (1.17:1.67)***
75 2.28 2.15 0.94 (0.73:1.22) 1.92 2.21 1.15 (0.91:1.47)
Note: Wald statistics are significant at the: 
p <.05
p < .01 






Table 12: Validation Analysis: Predicted odds and adjusted odds ratios of any Unsafe Driver Action by
Opioid Analgesic exposure, driver age, and sex
Female Drivers Male Drivers
Odds Ratio (95% Cl) Odds Ratio (95% Cl)
Age
25 1.69 (1.17:2.44)** 1.76(1.27:2.44)***
35 1.71 (1.31:2.24)*** 1.78(1.43:2.23)***
45 1.64 (1.25:2.15)*** 1.71 (1.36:2.15)***
55 1.48 (1.12:1.96)** 1.55(1.21:1.97)***
65 1.27 (0.96:1.68) 1.32(1.04:1.68)*
75 1.03 (0.72:1.46) 1.07 (0.78:1.46)
**
* * *










Figure 3: Predicted Odds of an Unsafe Driver Action by Opioid Analgesic exposure by driver age by sex,
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Figure 4: Odds ratios of an Unsafe Driver Action by Opioid Analgesic exposure by driver age and sex, with











Appendix A: Driver Related Factors
20 Leaving Vehicle Unattended in Roadway
21 Overloading or Improper Loading of Vehicle with Passengers or Cargo
22 Towing or Pushing Vehicle Improperly
23 Failing to [Dim Lights or, Since 1995] Have Lights on When Required
24 Operating without Required Equipment
25 Creating Unlawful Noise or Using Equipment Prohibited by Law
26 Following Improperly
27 Improper or Erratic Lane Changing
28 Failure to Keep in Proper Lane or Running off Road
29 Illegal Driving on Road Shoulder, in Ditch, on Sidewalk, on Median
30 Making Improper Entry to or Exit from Trafficway
32 Opening Closure into Moving Traffic or While Vehicle is in Motion (Since 
2001)
33 Passing where Prohibited by Posted Signs, Pavement Markings, Hill or 
Curve, or School Bus Displaying Warning not to Pass
34 Passing on Wrong Side
35 Passing with Insufficient Distance or Inadequate Visibility or Failing to 
Yield to Overtaking Vehicle
36 Operating the Vehicle in Other Erratic, Reckless, Careless or Negligent 
Manner [or Operating at Erratic or Suddenly Changing Speeds, Since 
1995]
37 High-Speed Chase with Police in Pursuit
38 Failure to Yield Right of Way
39 Failure to Obey Traffic Signs, Traffic Control Devices or Traffic Officers, 
Failure to Observe Safety Zone Traffic Laws
40 Passing Through or Around Barrier Positioned to Prohibit or Channel 
Traffic
41 Failure to Observe Warnings or Instructions on Vehicles Displaying Them
42 Failure to Signal Intentions
43 Giving Wrong Signal
44 Driving too Fast for Conditions or in Excess of Posted Speed Limit
45 Driving Less than Posted Maximum
46 Operating at Erratic or Suddenly Changing Speeds
47 Making Right Turn from Left Turn Lane or Making Left Turn from Right 
Turn Lane
48 Making Improper Turn
50 Driving Wrong Way on One-Way Trafficway
51 Driving on Wrong Side of Road [(Intentionally or Unintentionally) Since 
1995]
52 Operator Inexperience
53 Unfamiliar with Roadway
54 Stopping in Roadway (Vehicle not Abandoned)
55 Underriding a Parked Truck
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57 Locked Wheel
58 Overcorrecting (Since 1995)
59 Getting Off/Out of or On/In to a Vehicle
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Appendix B: List of Abbreviations
BAG: Blood Alcohol Content.
Cl: Confidence Interval.
CNS: Central Nervous System.
COAT: Chronic Opioid Analgesic Therapy.
DUI: Driving Under the Influence (of either alcohol or drugs).
DWI: Driving While Intoxicated (from either alcohol or drugs).
PARS: Fatality Analysis Reporting System.
FTP: File Transfer Protocol.
NHTSA: National Highway Traffic Safety Administration.
NSAID: Non-Steroidal Anti-Inflammatory Drug.
OR(s): Odds Ratio(s).
PCP: Phencyclidine of the chemical name Phenylcyclohexylpiperidine.
PCs: Predicted Odds.
SDLP: Standard Deviation of Lateral Position.
SQL: Structured Query Language.
UDA(s): Unsafe Driver Action(s).
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